Header Logo

Lynn

Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Reeves DB, Mayer BT, deCamp AC, Huang Y, Zhang B, Carpp LN, Magaret CA, Juraska M, Gilbert PB, Montefiori DC, Bar KJ, Cardozo-Ojeda EF, Schiffer JT, Rossenkhan R, Edlefsen P, Morris L, Mkhize NN, Williamson C, Mullins JI, Seaton KE, Tomaras GD, Andrew P, Mgodi N, Ledgerwood JE, Cohen MS, Corey L, Naidoo L, Orrell C, Goepfert PA, Casapia M, Sobieszczyk ME, Karuna ST, Edupuganti S. Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials. Nat Commun. 2024 Mar 22; 15(1):2575. PMID: 38519455; PMCID: PMC10959920.
      Citations:    Fields:    
    2. Juraska M, Bai H, deCamp AC, Magaret CA, Li L, Gillespie K, Carpp LN, Giorgi EE, Ludwig J, Molitor C, Hudson A, Williamson BD, Espy N, Simpkins B, Rudnicki E, Shao D, Rossenkhan R, Edlefsen PT, Westfall DH, Deng W, Chen L, Zhao H, Bhattacharya T, Pankow A, Murrell B, Yssel A, Matten D, York T, Beaume N, Gwashu-Nyangiwe A, Ndabambi N, Thebus R, Karuna ST, Morris L, Montefiori DC, Hural JA, Cohen MS, Corey L, Rolland M, Gilbert PB, Williamson C, Mullins JI. Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features. Proc Natl Acad Sci U S A. 2024 Jan 23; 121(4):e2308942121. PMID: 38241441; PMCID: PMC10823214.
      Citations: 1     Fields:    Translation:HumansCells
    3. Reeves DB, Mayer BT, deCamp AC, Huang Y, Zhang B, Carpp LN, Magaret CA, Juraska M, Gilbert PB, Montefiori DC, Bar KJ, Cardozo-Ojeda EF, Schiffer JT, Rossenkhan R, Edlefsen P, Morris L, Mkhize NN, Williamson C, Mullins JI, Seaton KE, Tomaras GD, Andrew P, Mgodi N, Ledgerwood JE, Cohen MS, Corey L, Naidoo L, Orrell C, Goepfert PA, Casapia M, Sobieszczyk ME, Karuna ST, Edupuganti S. High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials. Nat Commun. 2023 Dec 14; 14(1):8299. PMID: 38097552; PMCID: PMC10721814.
      Citations:    Fields:    Translation:HumansCells
    4. Mahomed S, Garrett N, Potloane D, Sikazwe IT, Capparelli E, Harkoo I, Gengiah TN, Zuma NY, Osman F, Mansoor L, Archary D, Myeni N, Radebe P, Samsunder N, Doria-Rose N, Carlton K, Gama L, Koup RA, Narpala S, Serebryannyy L, Moore P, Williamson C, Pozzetto B, Hankins C, Morris L, Karim QA, Abdool Karim S. Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial. BMJ Open. 2023 08 28; 13(8):e076843. PMID: 37640457; PMCID: PMC10462944.
      Citations:    Fields:    Translation:HumansAnimalsCTClinical Trials
    5. Mkhize NN, Yssel AEJ, Kaldine H, van Dorsten RT, Woodward Davis AS, Beaume N, Matten D, Lambson B, Modise T, Kgagudi P, York T, Westfall DH, Giorgi EE, Korber B, Anthony C, Mapengo RE, Bekker V, Domin E, Eaton A, Deng W, DeCamp A, Huang Y, Gilbert PB, Gwashu-Nyangiwe A, Thebus R, Ndabambi N, Mielke D, Mgodi N, Karuna S, Edupuganti S, Seaman MS, Corey L, Cohen MS, Hural J, McElrath MJ, Mullins JI, Montefiori D, Moore PL, Williamson C, Morris L. Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials. PLoS Pathog. 2023 06; 19(6):e1011469. PMID: 37384759; PMCID: PMC10337935.
      Citations: 5     Fields:    Translation:HumansCells
    6. Seaton KE, Huang Y, Karuna S, Heptinstall JR, Brackett C, Chiong K, Zhang L, Yates NL, Sampson M, Rudnicki E, Juraska M, deCamp AC, Edlefsen PT, Mullins JI, Williamson C, Rossenkhan R, Giorgi EE, Kenny A, Angier H, Randhawa A, Weiner JA, Rojas M, Sarzotti-Kelsoe M, Zhang L, Sawant S, Ackerman ME, McDermott AB, Mascola JR, Hural J, McElrath MJ, Andrew P, Hidalgo JA, Clark J, Laher F, Orrell C, Frank I, Gonzales P, Edupuganti S, Mgodi N, Corey L, Morris L, Montefiori D, Cohen MS, Gilbert PB, Tomaras GD. Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition. EBioMedicine. 2023 Jul; 93:104590. PMID: 37300931; PMCID: PMC10363420.
      Citations: 7     Fields:    Translation:HumansCells
    7. Mahomed S, Garrett N, Capparelli EV, Osman F, Mkhize NN, Harkoo I, Gengiah TN, Mansoor LE, Baxter C, Archary D, Yende-Zuma N, Samsunder N, Carlton K, Narpala S, McDermott AB, Doria-Rose NA, Moore PL, Morris L, Abdool Karim Q, Mascola JR, Abdool Karim SS. Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial. Lancet HIV. 2023 04; 10(4):e230-e243. PMID: 37001964.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    8. Pilewski KA, Wall S, Richardson SI, Manamela NP, Clark K, Hermanus T, Binshtein E, Venkat R, Sautto GA, Kramer KJ, Shiakolas AR, Setliff I, Salas J, Mapengo RE, Suryadevara N, Brannon JR, Beebout CJ, Parks R, Raju N, Frumento N, Walker LM, Fechter EF, Qin JS, Murji AA, Janowska K, Thakur B, Lindenberger J, May AJ, Huang X, Sammour S, Acharya P, Carnahan RH, Ross TM, Haynes BF, Hadjifrangiskou M, Crowe JE, Bailey JR, Kalams S, Morris L, Georgiev IS. Functional HIV-1/HCV cross-reactive antibodies isolated from a chronically co-infected donor. Cell Rep. 2023 02 28; 42(2):112044. PMID: 36708513; PMCID: PMC10372200.
      Citations: 4     Fields:    Translation:HumansCells
    9. Moyo-Gwete T, Scheepers C, Makhado Z, Kgagudi P, Mzindle NB, Ziki R, Madzorera S, Manamela NP, Ayres F, Lambson BE, Richardson SI, Morris L, Moore PL. Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms. Sci Rep. 2022 10 01; 12(1):16473. PMID: 36182959; PMCID: PMC9526727.
      Citations: 4     Fields:    Translation:HumansCells
    10. Scheepers C, Kgagudi P, Mzindle N, Gray ES, Moyo-Gwete T, Lambson BE, Oosthuysen B, Mabvakure B, Garrett NJ, Abdool Karim SS, Morris L, Moore PL. Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies. PLoS Pathog. 2022 09; 18(9):e1010450. PMID: 36054228; PMCID: PMC9477419.
      Citations:    Fields:    Translation:HumansCells
    11. Gilbert PB, Huang Y, deCamp AC, Karuna S, Zhang Y, Magaret CA, Giorgi EE, Korber B, Edlefsen PT, Rossenkhan R, Juraska M, Rudnicki E, Kochar N, Huang Y, Carpp LN, Barouch DH, Mkhize NN, Hermanus T, Kgagudi P, Bekker V, Kaldine H, Mapengo RE, Eaton A, Domin E, West C, Feng W, Tang H, Seaton KE, Heptinstall J, Brackett C, Chiong K, Tomaras GD, Andrew P, Mayer BT, Reeves DB, Sobieszczyk ME, Garrett N, Sanchez J, Gay C, Makhema J, Williamson C, Mullins JI, Hural J, Cohen MS, Corey L, Montefiori DC, Morris L. Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. Nat Med. 2022 09; 28(9):1924-1932. PMID: 35995954; PMCID: PMC9499869.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    12. Crowley AR, Richardson SI, Tuyishime M, Jennewein M, Bailey MJ, Lee J, Alter G, Ferrari G, Morris L, Ackerman ME. Functional consequences of allotypic polymorphisms in human immunoglobulin G subclasses. Immunogenetics. 2023 02; 75(1):1-16. PMID: 35904629; PMCID: PMC9845132.
      Citations: 6     Fields:    Translation:Humans
    13. Sheward DJ, Hermanus T, Murrell B, Garrett N, Abdool Karim SS, Morris L, Moore PL, Williamson C. HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing Antibodies. J Virol. 2022 07 27; 96(14):e0032422. PMID: 35758668; PMCID: PMC9327685.
      Citations:    Fields:    Translation:HumansCells
    14. Sacks D, Wiehe K, Morris L, Moore PL. Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage. J Virol. 2022 05 25; 96(10):e0027022. PMID: 35510865.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    15. Suchard MS, Martinson N, Malfeld S, de Assis Rosa D, Mackelprang RD, Lingappa J, Hou X, Rees H, Delany-Moretlwe S, Goldfein H, Ranchod H, Coetzee D, Otwombe K, Morris L, Tiemessen CT, Savulescu DM. Alloimmunity to Class 2 Human Leucocyte Antigens May Reduce HIV-1 Acquisition - A Nested Case-Control Study in HIV-1 Serodiscordant Couples. Front Immunol. 2022; 13:813412. PMID: 35401581; PMCID: PMC8987441.
      Citations:    Fields:    Translation:HumansCells
    16. Walker LM, Shiakolas AR, Venkat R, Liu ZA, Wall S, Raju N, Pilewski KA, Setliff I, Murji AA, Gillespie R, Makoah NA, Kanekiyo M, Connors M, Morris L, Georgiev IS. High-Throughput B Cell Epitope Determination by Next-Generation Sequencing. Front Immunol. 2022; 13:855772. PMID: 35401559; PMCID: PMC8984479.
      Citations: 5     Fields:    Translation:HumansCells
    17. Weiss S, Itri V, Pan R, Jiang X, Luo CC, Morris L, Malherbe DC, Barnette P, Alexander J, Kong XP, Haigwood NL, Hessell AJ, Duerr R, Zolla-Pazner S. Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines. Nat Commun. 2022 02 16; 13(1):903. PMID: 35173151; PMCID: PMC8850611.
      Citations: 5     Fields:    Translation:AnimalsCellsPHPublic Health
    18. Mahomed S, Garrett N, Capparelli EV, Osman F, Harkoo I, Yende-Zuma N, Gengiah TN, Archary D, Samsunder N, Baxter C, Mkhize NN, Modise T, Carlton K, McDermott A, Moore PL, Abdool Karim Q, Barouch DH, Fast PE, Mascola JR, Ledgerwood JE, Morris L, Abdool Karim SS. Safety and pharmacokinetics of monoclonal antibodies VRC07-523LS and PGT121 administered subcutaneously for HIV prevention. J Infect Dis. 2022 Feb 04. PMID: 35134995.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    19. van Dorsten RT, Reh L, Trkola A, Morris L, Moore PL. Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission. J Virol. 2022 02 23; 96(4):e0193421. PMID: 34935437; PMCID: PMC8865436.
      Citations: 2     Fields:    Translation:HumansCells
    20. Murji AA, Raju N, Qin JS, Kaldine H, Janowska K, Fechter EF, Mapengo R, Scheepers C, Setliff I, Acharya P, Morris L, Georgiev IS. Sequence and functional characterization of a public HIV-specific antibody clonotype. iScience. 2022 Jan 21; 25(1):103564. PMID: 34984325; PMCID: PMC8692997.
      Citations: 1     
    21. Morris L. mRNA vaccines offer hope for HIV. Nat Med. 2021 12; 27(12):2082-2084. PMID: 34887576.
      Citations: 6     Fields:    Translation:Humans
    22. Mielke D, Bandawe G, Zheng J, Jones J, Abrahams MR, Bekker V, Ochsenbauer C, Garrett N, Abdool Karim S, Moore PL, Morris L, Montefiori D, Anthony C, Ferrari G, Williamson C. ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection. PLoS Pathog. 2021 11; 17(11):e1010046. PMID: 34788337; PMCID: PMC8598021.
      Citations: 6     Fields:    Translation:HumansCells
    23. Mielke D, Stanfield-Oakley S, Borate B, Fisher LH, Faircloth K, Tuyishime M, Greene K, Gao H, Williamson C, Morris L, Ochsenbauer C, Tomaras G, Haynes BF, Montefiori D, Pollara J, deCamp AC, Ferrari G. Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies. J Virol. 2022 01 26; 96(2):e0164321. PMID: 34730393; PMCID: PMC8791251.
      Citations: 2     Fields:    Translation:HumansCells
    24. van Dorsten RT, Wagh K, Moore PL, Morris L. Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth. Front Immunol. 2021; 12:734110. PMID: 34603312; PMCID: PMC8481832.
      Citations: 4     Fields:    Translation:HumansCells
    25. Richardson SI, Ayres F, Manamela NP, Oosthuysen B, Makhado Z, Lambson BE, Morris L, Moore PL. HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function. Front Immunol. 2021; 12:733958. PMID: 34566999; PMCID: PMC8462932.
      Citations: 8     Fields:    Translation:HumansCells
    26. Huang Y, Zhang L, Eaton A, Mkhize NN, Carpp LN, Rudnicki E, DeCamp A, Juraska M, Randhawa A, McDermott A, Ledgerwood J, Andrew P, Karuna S, Edupuganti S, Mgodi N, Cohen M, Corey L, Mascola J, Gilbert PB, Morris L, Montefiori DC. Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. Hum Vaccin Immunother. 2022 12 31; 18(1):1908030. PMID: 34213402; PMCID: PMC8928800.
      Citations: 5     Fields:    Translation:HumansCells
    27. Murji AA, Qin JS, Hermanus T, Morris L, Georgiev IS. Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms. Viruses. 2021 07 02; 13(7). PMID: 34372503; PMCID: PMC8310022.
      Citations: 4     Fields:    Translation:AnimalsCellsPHPublic Health
    28. Shiakolas AR, Kramer KJ, Wrapp D, Richardson SI, Schäfer A, Wall S, Wang N, Janowska K, Pilewski KA, Venkat R, Parks R, Manamela NP, Raju N, Fechter EF, Holt CM, Suryadevara N, Chen RE, Martinez DR, Nargi RS, Sutton RE, Ledgerwood JE, Graham BS, Diamond MS, Haynes BF, Acharya P, Carnahan RH, Crowe JE, Baric RS, Morris L, McLellan JS, Georgiev IS. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Rep Med. 2021 06 15; 2(6):100313. PMID: 34056628; PMCID: PMC8139315.
      Citations: 45     Fields:    Translation:HumansAnimalsCells
    29. Moyo-Gwete T, Madzivhandila M, Makhado Z, Ayres F, Mhlanga D, Oosthuysen B, Lambson BE, Kgagudi P, Tegally H, Iranzadeh A, Doolabh D, Tyers L, Chinhoyi LR, Mennen M, Skelem S, Marais G, Wibmer CK, Bhiman JN, Ueckermann V, Rossouw T, Boswell M, de Oliveira T, Williamson C, Burgers WA, Ntusi N, Morris L, Moore PL. Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). N Engl J Med. 2021 06 03; 384(22):2161-2163. PMID: 33826816; PMCID: PMC8063886.
      Citations: 89     Fields:    Translation:HumansCells
    30. Corey L, Gilbert PB, Juraska M, Montefiori DC, Morris L, Karuna ST, Edupuganti S, Mgodi NM, deCamp AC, Rudnicki E, Huang Y, Gonzales P, Cabello R, Orrell C, Lama JR, Laher F, Lazarus EM, Sanchez J, Frank I, Hinojosa J, Sobieszczyk ME, Marshall KE, Mukwekwerere PG, Makhema J, Baden LR, Mullins JI, Williamson C, Hural J, McElrath MJ, Bentley C, Takuva S, Gomez Lorenzo MM, Burns DN, Espy N, Randhawa AK, Kochar N, Piwowar-Manning E, Donnell DJ, Sista N, Andrew P, Kublin JG, Gray G, Ledgerwood JE, Mascola JR, Cohen MS, HVTN 704/HPTN 085 and HVTN 703/HPTN 081 Study Teams. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. N Engl J Med. 2021 03 18; 384(11):1003-1014. PMID: 33730454; PMCID: PMC8189692.
      Citations: 179     Fields:    Translation:HumansCellsCTClinical Trials
    31. Moyo-Gwete T, Madzivhandila M, Makhado Z, Ayres F, Mhlanga D, Oosthuysen B, Lambson BE, Kgagudi P, Tegally H, Iranzadeh A, Doolabh D, Tyers L, Chinhoyi LR, Mennen M, Skelem S, Marais G, Wibmer CK, Bhiman JN, Ueckermann V, Rossouw T, Boswell M, de Oliveira T, Williamson C, Burgers WA, Ntusi N, Morris L, Moore PL. SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies. bioRxiv. 2021 Mar 11. PMID: 33688657; PMCID: PMC7941631.
      Citations: 1     
    32. Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, Lambson BE, de Oliveira T, Vermeulen M, van der Berg K, Rossouw T, Boswell M, Ueckermann V, Meiring S, von Gottberg A, Cohen C, Morris L, Bhiman JN, Moore PL. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021 04; 27(4):622-625. PMID: 33654292.
      Citations: 742     Fields:    Translation:HumansCells
    33. Chege GK, Adams CH, Keyser AT, Bekker V, Morris L, Villinger FJ, Williamson AL, Chapman RE. Infection of Chinese Rhesus Monkeys with a Subtype C SHIV Resulted in Attenuated In Vivo Viral Replication Despite Successful Animal-to-Animal Serial Passages. Viruses. 2021 03 02; 13(3). PMID: 33801437; PMCID: PMC7998229.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    34. Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, Lambson BE, de Oliveira T, Vermeulen M, van der Berg K, Rossouw T, Boswell M, Ueckermann V, Meiring S, von Gottberg A, Cohen C, Morris L, Bhiman JN, Moore PL. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv. 2021 Mar 01. PMID: 33501446; PMCID: PMC7836116.
      Citations: 12     
    35. Hosseinipour MC, Innes C, Naidoo S, Mann P, Hutter J, Ramjee G, Sebe M, Maganga L, Herce ME, deCamp AC, Marshall K, Dintwe O, Andersen-Nissen E, Tomaras GD, Mkhize N, Morris L, Jensen R, Miner MD, Pantaleo G, Ding S, Van Der Meeren O, Barnett SW, McElrath MJ, Corey L, Kublin JG, HVTN 111 Protocol Team. Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein. Clin Infect Dis. 2021 01 23; 72(1):50-60. PMID: 31900486; PMCID: PMC7823071.
      Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
    36. Shiakolas AR, Kramer KJ, Wrapp D, Richardson SI, Schäfer A, Wall S, Wang N, Janowska K, Pilewski KA, Venkat R, Parks R, Manamela NP, Raju N, Fechter EF, Holt CM, Suryadevara N, Chen RE, Martinez DR, Nargi RS, Sutton RE, Ledgerwood JE, Graham BS, Diamond MS, Haynes BF, Acharya P, Carnahan RH, Crowe JE, Baric RS, Morris L, McLellan JS, Georgiev IS. Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions. bioRxiv. 2020 Dec 20. PMID: 33398266; PMCID: PMC7781301.
      Citations: 1     
    37. Goes LR, Sajani A, Sivro A, Olowojesiku R, Ray JC, Perrone I, Yolitz J, Girard A, Leyre L, Wibmer CK, Morris L, Gorini G, Franchini G, Mason RD, Roederer M, Mehandru S, Soares MA, Cicala C, Fauci AS, Arthos J. The V2 loop of HIV gp120 delivers costimulatory signals to CD4+ T cells through Integrin a4ß7 and promotes cellular activation and infection. Proc Natl Acad Sci U S A. 2020 12 22; 117(51):32566-32573. PMID: 33288704; PMCID: PMC7768698.
      Citations: 10     Fields:    Translation:HumansCells
    38. Mahomed S, Garrett N, Karim QA, Zuma NY, Capparelli E, Baxter C, Gengiah T, Archary D, Samsunder N, Rose ND, Moore P, Williamson C, Barouch DH, Fast PE, Pozzetto B, Hankins C, Carlton K, Ledgerwood J, Morris L, Mascola J, Abdool Karim S. Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial. BMJ Open. 2020 11 26; 10(11):e042247. PMID: 33243815; PMCID: PMC7692975.
      Citations: 21     Fields:    Translation:HumansCellsCTClinical Trials
    39. Scheepers C, Bekker V, Anthony C, Richardson SI, Oosthuysen B, Moyo T, Kgagudi P, Kitchin D, Nonyane M, York T, Mielke D, Mabvakure BM, Sheng Z, Lambson BE, Ismail A, Garrett NJ, Abdool Karim SS, Shapiro L, Williamson C, Morris L, Moore PL. Antibody Isotype Switching as a Mechanism to Counter HIV Neutralization Escape. Cell Rep. 2020 11 24; 33(8):108430. PMID: 33238131; PMCID: PMC7723817.
      Citations: 10     Fields:    Translation:HumansCells
    40. Basson AE, Charalambous S, Hoffmann CJ, Morris L. HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. PLoS One. 2020; 15(6):e0234937. PMID: 32555643; PMCID: PMC7302689.
      Citations: 3     Fields:    Translation:HumansCells
    41. Moodie Z, Walsh SR, Laher F, Maganga L, Herce ME, Naidoo S, Hosseinipour MC, Innes C, Bekker LG, Grunenberg N, Mann P, Yu C, deCamp AC, Miner MD, Yates NL, Heptinstall J, Mkhize NN, Dintwe O, Frahm N, Cohen KW, Allen M, Hutter J, Wagner R, Pantaleo G, McElrath MJ, Tomaras GD, Morris L, Montefiori DC, Andersen-Nissen E, Gray GE, Gilbert PB, Kublin JG, NIAID HVTN 100 and HVTN 111 trial teams. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. PLoS Med. 2020 05; 17(5):e1003117. PMID: 32442195; PMCID: PMC7244095.
      Citations: 5     Fields:    Translation:HumansCellsPHPublic Health
    42. Singh AA, Pooe O, Kwezi L, Lotter-Stark T, Stoychev SH, Alexandra K, Gerber I, Bhiman JN, Vorster J, Pauly M, Zeitlin L, Whaley K, Mach L, Steinkellner H, Morris L, Tsekoa TL, Chikwamba R. Plant-based production of highly potent anti-HIV antibodies with engineered posttranslational modifications. Sci Rep. 2020 04 10; 10(1):6201. PMID: 32277089; PMCID: PMC7148297.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    43. Gorman J, Chuang GY, Lai YT, Shen CH, Boyington JC, Druz A, Geng H, Louder MK, McKee K, Rawi R, Verardi R, Yang Y, Zhang B, Doria-Rose NA, Lin B, Moore PL, Morris L, Shapiro L, Mascola JR, Kwong PD. Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition. Cell Rep. 2020 04 07; 31(1):107488. PMID: 32268107.
      Citations: 38     Fields:    Translation:HumansCells
    44. Ndlovu B, Gounder K, Muema D, Raju N, Hermanus T, Mthethwa Q, Robertson K, Walker BD, Georgiev IS, Morris L, Moore PL, Ndung'u T. Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection. Virology. 2020 07; 546:1-12. PMID: 32275203; PMCID: PMC8186003.
      Citations: 1     Fields:    Translation:HumansCells
    45. Laher F, Moodie Z, Cohen KW, Grunenberg N, Bekker LG, Allen M, Frahm N, Yates NL, Morris L, Malahleha M, Mngadi K, Daniels B, Innes C, Saunders K, Grant S, Yu C, Gilbert PB, Phogat S, DiazGranados CA, Koutsoukos M, Van Der Meeren O, Bentley C, Mkhize NN, Pensiero MN, Mehra VL, Kublin JG, Corey L, Montefiori DC, Gray GE, McElrath MJ, Tomaras GD. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Med. 2020 02; 17(2):e1003038. PMID: 32092060; PMCID: PMC7039414.
      Citations: 23     Fields:    Translation:HumansCellsCTClinical Trials
    46. Ditse Z, Mkhize NN, Yin M, Keefer M, Montefiori DC, Tomaras GD, Churchyard G, Mayer KH, Karuna S, Morgan C, Bekker LG, Mlisana K, Gray G, Moodie Z, Gilbert P, Moore PL, Williamson C, Morris L. Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. mSphere. 2020 Jan 29; 5(1). PMID: 31996422; PMCID: PMC6992371.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    47. van Dorsten RT, Lambson BE, Wibmer CK, Weinberg MS, Moore PL, Morris L. Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope. J Virol. 2020 01 06; 94(2). PMID: 31619559; PMCID: PMC6955269.
      Citations: 12     Fields:    Translation:HumansCells
    48. Richardson SI, Lambson BE, Crowley AR, Bashirova A, Scheepers C, Garrett N, Abdool Karim S, Mkhize NN, Carrington M, Ackerman ME, Moore PL, Morris L. IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. PLoS Pathog. 2019 12; 15(12):e1008064. PMID: 31841557; PMCID: PMC6936867.
      Citations: 50     Fields:    Translation:Humans
    49. Mielke D, Bandawe G, Pollara J, Abrahams MR, Nyanhete T, Moore PL, Thebus R, Yates NL, Kappes JC, Ochsenbauer C, Garrett N, Abdool Karim S, Tomaras GD, Montefiori D, Morris L, Ferrari G, Williamson C. Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway. Front Immunol. 2019; 10:2875. PMID: 31921139; PMCID: PMC6919271.
      Citations: 16     Fields:    Translation:HumansCells
    50. Bekker LG, Tatoud R, Dabis F, Feinberg M, Kaleebu P, Marovich M, Ndung'u T, Russell N, Johnson J, Luba M, Fauci AS, Morris L, Pantaleo G, Buchbinder S, Gray G, Vekemans J, Kim JH, Levy Y, Corey L, Shattock R, Makanga M, Williamson C, Dieffenbach C, Goodenow MM, Shao Y, Staprans S, Warren M, Johnston MI. The complex challenges of HIV vaccine development require renewed and expanded global commitment. Lancet. 2020 02 01; 395(10221):384-388. PMID: 31806257.
      Citations: 30     Fields:    Translation:HumansPHPublic Health
    51. Setliff I, Shiakolas AR, Pilewski KA, Murji AA, Mapengo RE, Janowska K, Richardson S, Oosthuysen C, Raju N, Ronsard L, Kanekiyo M, Qin JS, Kramer KJ, Greenplate AR, McDonnell WJ, Graham BS, Connors M, Lingwood D, Acharya P, Morris L, Georgiev IS. High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. Cell. 2019 12 12; 179(7):1636-1646.e15. PMID: 31787378; PMCID: PMC7158953.
      Citations: 132     Fields:    Translation:HumansCells
    52. Mabvakure BM, Rott R, Dobrowsky L, Van Heusden P, Morris L, Scheepers C, Moore PL. Advancing HIV Vaccine Research With Low-Cost High-Performance Computing Infrastructure: An Alternative Approach for Resource-Limited Settings. Bioinform Biol Insights. 2019; 13:1177932219882347. PMID: 35173421; PMCID: PMC8842485.
      Citations:    
    53. Margolin E, Chapman R, Meyers AE, van Diepen MT, Ximba P, Hermanus T, Crowther C, Weber B, Morris L, Williamson AL, Rybicki EP. Production and Immunogenicity of Soluble Plant-Produced HIV-1 Subtype C Envelope gp140 Immunogens. Front Plant Sci. 2019; 10:1378. PMID: 31737007; PMCID: PMC6831737.
      Citations: 19     
    54. Gray GE, Huang Y, Grunenberg N, Laher F, Roux S, Andersen-Nissen E, De Rosa SC, Flach B, Randhawa AK, Jensen R, Swann EM, Bekker LG, Innes C, Lazarus E, Morris L, Mkhize NN, Ferrari G, Montefiori DC, Shen X, Sawant S, Yates N, Hural J, Isaacs A, Phogat S, DiazGranados CA, Lee C, Sinangil F, Michael NL, Robb ML, Kublin JG, Gilbert PB, McElrath MJ, Tomaras GD, Corey L. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med. 2019 09 18; 11(510). PMID: 31534016; PMCID: PMC7199879.
      Citations: 44     Fields:    Translation:HumansCellsPHPublic Health
    55. Hunt GM, Ledwaba J, Salimo A, Kalimashe M, Dinh TH, Jackson D, Sherman G, Puren A, Ngandu NK, Lombard C, Morris L, Goga A. Prevalence of HIV-1 drug resistance amongst newly diagnosed HIV-infected infants age 4-8 weeks, enrolled in three nationally representative PMTCT effectiveness surveys, South Africa: 2010, 2011-12 and 2012-13. BMC Infect Dis. 2019 Sep 16; 19(Suppl 1):787. PMID: 31526373; PMCID: PMC6745779.
      Citations: 9     Fields:    Translation:HumansCellsPHPublic Health
    56. Sacks D, Bhiman JN, Wiehe K, Gorman J, Kwong PD, Morris L, Moore PL. Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage. PLoS Pathog. 2019 09; 15(9):e1008005. PMID: 31479499; PMCID: PMC6743783.
      Citations: 4     Fields:    Translation:HumansCells
    57. Morris L. Engineered HIV antibody passes muster. Lancet HIV. 2019 10; 6(10):e641-e642. PMID: 31473166.
      Citations: 2     Fields:    Translation:HumansCells
    58. Mahomed S, Garrett N, Capparelli E, Baxter C, Zuma NY, Gengiah T, Archary D, Moore P, Samsunder N, Barouch DH, Mascola J, Ledgerwood J, Morris L, Abdool Karim S. Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial. BMJ Open. 2019 07 03; 9(7):e030283. PMID: 31272988; PMCID: PMC6615816.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    59. Roider J, Porterfield JZ, Ogongo P, Muenchhoff M, Adland E, Groll A, Morris L, Moore PL, Ndung'u T, Kløverpris H, Goulder PJR, Leslie A. Plasma IL-5 but Not CXCL13 Correlates With Neutralization Breadth in HIV-Infected Children. Front Immunol. 2019; 10:1497. PMID: 31333650; PMCID: PMC6615198.
      Citations: 3     Fields:    Translation:HumansCells
    60. van den Berg FT, Makoah NA, Ali SA, Scott TA, Mapengo RE, Mutsvunguma LZ, Mkhize NN, Lambson BE, Kgagudi PD, Crowther C, Abdool Karim SS, Balazs AB, Weinberg MS, Ely A, Arbuthnot PB, Morris L. AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region. Mol Ther Methods Clin Dev. 2019 Sep 13; 14:100-112. PMID: 31334303; PMCID: PMC6616373.
      Citations: 19     
    61. Mabvakure BM, Lambson BE, Ramdayal K, Masson L, Kitchin D, Allam M, Abdool Karim S, Williamson C, Passmore JA, Martin DP, Scheepers C, Moore PL, Harkins GW, Morris L. Evidence for both Intermittent and Persistent Compartmentalization of HIV-1 in the Female Genital Tract. J Virol. 2019 05 15; 93(10). PMID: 30842323; PMCID: PMC6498054.
      Citations: 4     Fields:    Translation:HumansCells
    62. Ledwaba J, Sayed Y, Pillay V, Morris L, Hunt G. Low Frequency of Protease Inhibitor Resistance Mutations and Insertions in HIV-1 Subtype C Protease Inhibitor-Naïve Sequences. AIDS Res Hum Retroviruses. 2019 07; 35(7):673-678. PMID: 30793914.
      Citations: 4     Fields:    Translation:HumansCells
    63. van Diepen MT, Chapman R, Douglass N, Galant S, Moore PL, Margolin E, Ximba P, Morris L, Rybicki EP, Williamson AL. Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus. J Virol. 2019 04 15; 93(8). PMID: 30760570; PMCID: PMC6450106.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    64. Chimukangara B, Lessells RJ, Rhee SY, Giandhari J, Kharsany ABM, Naidoo K, Lewis L, Cawood C, Khanyile D, Ayalew KA, Diallo K, Samuel R, Hunt G, Vandormael A, Stray-Pedersen B, Gordon M, Makadzange T, Kiepiela P, Ramjee G, Ledwaba J, Kalimashe M, Morris L, Parikh UM, Mellors JW, Shafer RW, Katzenstein D, Moodley P, Gupta RK, Pillay D, Abdool Karim SS, de Oliveira T. Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000-2016: A Pooled Sequence Analysis. EClinicalMedicine. 2019 Mar; 9:26-34. PMID: 31143879; PMCID: PMC6510720.
      Citations: 37     
    65. Mabvakure BM, Scheepers C, Garrett N, Abdool Karim S, Williamson C, Morris L, Moore PL. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies. J Virol. 2019 03 15; 93(6). PMID: 30567996; PMCID: PMC6401460.
      Citations: 8     Fields:    Translation:HumansCellsPHPublic Health
    66. Williams A, Basson A, Achilonu I, Dirr HW, Morris L, Sayed Y. Double trouble? Gag in conjunction with double insert in HIV protease contributes to reduced DRV susceptibility. Biochem J. 2019 01 31; 476(2):375-384. PMID: 30573649.
      Citations: 2     Fields:    Translation:HumansCells
    67. Hunt GM, Ledwaba J, Kalimashe M, Salimo A, Cibane S, Singh B, Puren A, Dean NE, Morris L, Jordan MR. Provincial and national prevalence estimates of transmitted HIV-1 drug resistance in South Africa measured using two WHO-recommended methods. Antivir Ther. 2019; 24(3):203-210. PMID: 30741163.
      Citations: 3     Fields:    Translation:HumansCellsPHPublic Health
    68. Zondagh J, Basson AE, Achilonu I, Morris L, Dirr HW, Sayed Y. Drug susceptibility and replication capacity of a rare HIV-1 subtype C protease hinge region variant. Antivir Ther. 2019; 24(5):333-342. PMID: 30958309.
      Citations:    Fields:    Translation:HumansCells
    69. van Diepen MT, Chapman R, Moore PL, Margolin E, Hermanus T, Morris L, Ximba P, Rybicki EP, Williamson AL. The adjuvant AlhydroGel elicits higher antibody titres than AddaVax when combined with HIV-1 subtype C gp140 from CAP256. PLoS One. 2018; 13(12):e0208310. PMID: 30557314; PMCID: PMC6296668.
      Citations: 14     Fields:    Translation:HumansCellsPHPublic Health
    70. van Eeden C, Wibmer CK, Scheepers C, Richardson SI, Nonyane M, Lambson B, Mkhize NN, Vijayakumar B, Sheng Z, Stanfield-Oakley S, Bhiman JN, Bekker V, Hermanus T, Mabvakure B, Ismail A, Moody MA, Wiehe K, Garrett N, Karim SA, Dirr H, Fernandes MA, Sayed Y, Shapiro L, Ferrari G, Haynes BF, Moore PL, Morris L. V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. Cell Rep. 2018 12 11; 25(11):3123-3135.e6. PMID: 30540944; PMCID: PMC6342559.
      Citations: 16     Fields:    Translation:HumansCells
    71. Wibmer CK, Richardson SI, Yolitz J, Cicala C, Arthos J, Moore PL, Morris L. Common helical V1V2 conformations of HIV-1 Envelope expose the a4ß7 binding site on intact virions. Nat Commun. 2018 10 26; 9(1):4489. PMID: 30367034; PMCID: PMC6203816.
      Citations: 16     Fields:    Translation:HumansCells
    72. Delany-Moretlwe S, Lombard C, Baron D, Bekker LG, Nkala B, Ahmed K, Sebe M, Brumskine W, Nchabeleng M, Palanee-Philips T, Ntshangase J, Sibiya S, Smith E, Panchia R, Myer L, Schwartz JL, Marzinke M, Morris L, Brown ER, Doncel GF, Gray G, Rees H. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018 11; 18(11):1241-1250. PMID: 30507409.
      Citations: 41     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    73. Johnson EL, Doria-Rose NA, Gorman J, Bhiman JN, Schramm CA, Vu AQ, Law WH, Zhang B, Bekker V, Abdool Karim SS, Ippolito GC, Morris L, Moore PL, Kwong PD, Mascola JR, Georgiou G. Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation. Nat Commun. 2018 10 08; 9(1):4136. PMID: 30297708; PMCID: PMC6175870.
      Citations: 6     Fields:    Translation:HumansCells
    74. Sheward DJ, Marais J, Bekker V, Murrell B, Eren K, Bhiman JN, Nonyane M, Garrett N, Woodman ZL, Abdool Karim Q, Abdool Karim SS, Morris L, Moore PL, Williamson C. HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. Cell Host Microbe. 2018 10 10; 24(4):593-599.e3. PMID: 30269971; PMCID: PMC6185870.
      Citations: 16     Fields:    Translation:HumansCells
    75. Richardson SI, Crowther C, Mkhize NN, Morris L. Measuring the ability of HIV-specific antibodies to mediate trogocytosis. J Immunol Methods. 2018 12; 463:71-83. PMID: 30240705.
      Citations: 22     Fields:    Translation:HumansCells
    76. Roider J, Maehara T, Ngoepe A, Ramsuran D, Muenchhoff M, Adland E, Aicher T, Kazer SW, Jooste P, Karim F, Kuhn W, Shalek AK, Ndung'u T, Morris L, Moore PL, Pillai S, Kløverpris H, Goulder P, Leslie A. High-Frequency, Functional HIV-Specific T-Follicular Helper and Regulatory Cells Are Present Within Germinal Centers in Children but Not Adults. Front Immunol. 2018; 9:1975. PMID: 30258437; PMCID: PMC6143653.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    77. Lertjuthaporn S, Cicala C, Van Ryk D, Liu M, Yolitz J, Wei D, Nawaz F, Doyle A, Horowitch B, Park C, Lu S, Lou Y, Wang S, Pan R, Jiang X, Villinger F, Byrareddy SN, Santangelo PJ, Morris L, Wibmer CK, Biris K, Mason RD, Gorman J, Hiatt J, Martinelli E, Roederer M, Fujikawa D, Gorini G, Franchini G, Arakelyan A, Ansari AA, Pattanapanyasat K, Kong XP, Fauci AS, Arthos J. Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to a4ß7. PLoS Pathog. 2018 08; 14(8):e1007278. PMID: 30153309; PMCID: PMC6130882.
      Citations: 19     Fields:    Translation:AnimalsCellsPHPublic Health
    78. Ditse Z, Muenchhoff M, Adland E, Jooste P, Goulder P, Moore PL, Morris L. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes. J Virol. 2018 09 01; 92(17). PMID: 29950423; PMCID: PMC6096808.
      Citations: 38     Fields:    Translation:HumansCells
    79. Bekker LG, Moodie Z, Grunenberg N, Laher F, Tomaras GD, Cohen KW, Allen M, Malahleha M, Mngadi K, Daniels B, Innes C, Bentley C, Frahm N, Morris DE, Morris L, Mkhize NN, Montefiori DC, Sarzotti-Kelsoe M, Grant S, Yu C, Mehra VL, Pensiero MN, Phogat S, DiazGranados CA, Barnett SW, Kanesa-Thasan N, Koutsoukos M, Michael NL, Robb ML, Kublin JG, Gilbert PB, Corey L, Gray GE, McElrath MJ, HVTN 100 Protocol Team. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV. 2018 07; 5(7):e366-e378. PMID: 29898870; PMCID: PMC6028742.
      Citations: 59     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    80. Setliff I, McDonnell WJ, Raju N, Bombardi RG, Murji AA, Scheepers C, Ziki R, Mynhardt C, Shepherd BE, Mamchak AA, Garrett N, Karim SA, Mallal SA, Crowe JE, Morris L, Georgiev IS. Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection. Cell Host Microbe. 2018 06 13; 23(6):845-854.e6. PMID: 29861170; PMCID: PMC6002606.
      Citations: 53     Fields:    Translation:HumansCells
    81. Anthony C, York T, Bekker V, Matten D, Selhorst P, Ferreria RC, Garrett NJ, Abdool Karim SS, Morris L, Wood NT, Moore PL, Williamson C. Correction for Anthony et al., "Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope". J Virol. 2018 05 01; 92(9). PMID: 29654221; PMCID: PMC5899201.
      Citations:    Fields:    
    82. Richardson SI, Chung AW, Natarajan H, Mabvakure B, Mkhize NN, Garrett N, Abdool Karim S, Moore PL, Ackerman ME, Alter G, Morris L. HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. PLoS Pathog. 2018 04; 14(4):e1006987. PMID: 29630668; PMCID: PMC5908199.
      Citations: 47     Fields:    Translation:HumansCells
    83. Montefiori DC, Roederer M, Morris L, Seaman MS. Neutralization tiers of HIV-1. Curr Opin HIV AIDS. 2018 03; 13(2):128-136. PMID: 29266013; PMCID: PMC5802254.
      Citations: 62     Fields:    Translation:HumansAnimalsCells
    84. Reh L, Magnus C, Kadelka C, Kühnert D, Uhr T, Weber J, Morris L, Moore PL, Trkola A. Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage. PLoS Pathog. 2018 01; 14(1):e1006825. PMID: 29370298; PMCID: PMC5806907.
      Citations: 9     Fields:    Translation:HumansCells
    85. Serwanga J, Ssemwanga D, Muganga M, Nakiboneka R, Nakubulwa S, Kiwuwa-Muyingo S, Morris L, Redd AD, Quinn TC, Kaleebu P, HIV Superinfection Study Group. HIV-1 superinfection can occur in the presence of broadly neutralizing antibodies. Vaccine. 2018 01 25; 36(4):578-586. PMID: 29274699.
      Citations: 2     Fields:    Translation:HumansCells
    86. Hraber P, Rademeyer C, Williamson C, Seaman MS, Gottardo R, Tang H, Greene K, Gao H, LaBranche C, Mascola JR, Morris L, Montefiori DC, Korber B. Correction for Hraber et al., "Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments". J Virol. 2018 01 01; 92(1). PMID: 29242255; PMCID: PMC5730795.
      Citations:    Fields:    
    87. Morris L, Mkhize NN. Prospects for passive immunity to prevent HIV infection. PLoS Med. 2017 Nov; 14(11):e1002436. PMID: 29136030; PMCID: PMC5685477.
      Citations: 18     Fields:    Translation:HumansCells
    88. Hunt GM, Kainne Dokubo E, Takuva S, de Oliveira T, Ledwaba J, Dube N, Moodley P, Sabatier J, Deyde V, Morris L, Raizes E. Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa. J Antimicrob Chemother. 2017 11 01; 72(11):3222. PMID: 28961961.
      Citations: 2     Fields:    
    89. Hunt GM, Dokubo EK, Takuva S, de Oliveira T, Ledwaba J, Dube N, Moodley P, Sabatier J, Deyde V, Morris L, Raizes E. Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa. J Antimicrob Chemother. 2017 Nov 01; 72(11):3141-3148. PMID: 28981637.
      Citations: 14     Fields:    Translation:HumansCellsPHPublic Health
    90. Scheepers C, Chowdhury S, Wright WS, Campbell CT, Garrett NJ, Abdool Karim Q, Abdool Karim SS, Moore PL, Gildersleeve JC, Morris L. Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses. AIDS. 2017 10 23; 31(16):2199-2209. PMID: 28926408; PMCID: PMC5633525.
      Citations: 7     Fields:    Translation:HumansCells
    91. Rademeyer C, Korber B, Seaman MS, Giorgi EE, Thebus R, Robles A, Sheward DJ, Wagh K, Garrity J, Carey BR, Gao H, Greene KM, Tang H, Bandawe GP, Marais JC, Diphoko TE, Hraber P, Tumba N, Moore PL, Gray GE, Kublin J, McElrath MJ, Vermeulen M, Middelkoop K, Bekker LG, Hoelscher M, Maboko L, Makhema J, Robb ML, Karim SA, Karim QA, Kim JH, Hahn BH, Gao F, Swanstrom R, Morris L, Montefiori DC, Williamson C. Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. PLoS Pathog. 2017 Sep; 13(9):e1006641. PMID: 28945784; PMCID: PMC5612725.
      Citations:    Fields:    
    92. Hraber P, Rademeyer C, Williamson C, Seaman MS, Gottardo R, Tang H, Greene K, Gao H, LaBranche C, Mascola JR, Morris L, Montefiori DC, Korber B. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments. J Virol. 2017 10 01; 91(19). PMID: 28747500; PMCID: PMC5599761.
      Citations: 25     Fields:    Translation:HumansCells
    93. Mabuka JM, Dugast AS, Muema DM, Reddy T, Ramlakhan Y, Euler Z, Ismail N, Moodley A, Dong KL, Morris L, Walker BD, Alter G, Ndung'u T. Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross-Neutralizing Antibodies. Front Immunol. 2017; 8:1104. PMID: 28943879; PMCID: PMC5596076.
      Citations: 22     Fields:    
    94. Julg B, Tartaglia LJ, Keele BF, Wagh K, Pegu A, Sok D, Abbink P, Schmidt SD, Wang K, Chen X, Joyce MG, Georgiev IS, Choe M, Kwong PD, Doria-Rose NA, Le K, Louder MK, Bailer RT, Moore PL, Korber B, Seaman MS, Abdool Karim SS, Morris L, Koup RA, Mascola JR, Burton DR, Barouch DH. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci Transl Med. 2017 09 06; 9(406). PMID: 28878010; PMCID: PMC5755978.
      Citations: 72     Fields:    Translation:AnimalsCells
    95. Anthony C, York T, Bekker V, Matten D, Selhorst P, Ferreria RC, Garrett NJ, Karim SSA, Morris L, Wood NT, Moore PL, Williamson C. Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope. J Virol. 2017 09 15; 91(18). PMID: 28679760; PMCID: PMC5571269.
      Citations: 23     Fields:    Translation:HumansCells
    96. Shacklett BL, Derdeyn CA, Folayan MO, Landovitz RJ, Anthony C, Behrens AJ, Hope TJ, Landais E, Leal L, Marrazzo JM, Morris L, Mugo N, Ngure K, Noseda V, Ranasinghe S, Tully DC, Voronin Y, Warren M, Wibmer CK, Xie IY, Scarlatti G, Thyagarajan B. HIVR4P 2016, Partnering for Prevention: Conference Summary and Highlights. AIDS Res Hum Retroviruses. 2017 08; 33(8):749-759. PMID: 28649869; PMCID: PMC5564036.
      Citations:    Fields:    Translation:HumansPHPublic Health
    97. Bonsignori M, Kreider EF, Fera D, Meyerhoff RR, Bradley T, Wiehe K, Alam SM, Aussedat B, Walkowicz WE, Hwang KK, Saunders KO, Zhang R, Gladden MA, Monroe A, Kumar A, Xia SM, Cooper M, Louder MK, McKee K, Bailer RT, Pier BW, Jette CA, Kelsoe G, Williams WB, Morris L, Kappes J, Wagh K, Kamanga G, Cohen MS, Hraber PT, Montefiori DC, Trama A, Liao HX, Kepler TB, Moody MA, Gao F, Danishefsky SJ, Mascola JR, Shaw GM, Hahn BH, Harrison SC, Korber BT, Haynes BF. Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. Sci Transl Med. 2017 03 15; 9(381). PMID: 28298420; PMCID: PMC5562350.
      Citations: 110     Fields:    Translation:HumansCells
    98. Alam SM, Aussedat B, Vohra Y, Meyerhoff RR, Cale EM, Walkowicz WE, Radakovich NA, Anasti K, Armand L, Parks R, Sutherland L, Scearce R, Joyce MG, Pancera M, Druz A, Georgiev IS, Von Holle T, Eaton A, Fox C, Reed SG, Louder M, Bailer RT, Morris L, Abdool-Karim SS, Cohen M, Liao HX, Montefiori DC, Park PK, Fernández-Tejada A, Wiehe K, Santra S, Kepler TB, Saunders KO, Sodroski J, Kwong PD, Mascola JR, Bonsignori M, Moody MA, Danishefsky S, Haynes BF. Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Sci Transl Med. 2017 03 15; 9(381). PMID: 28298421; PMCID: PMC5562351.
      Citations: 49     Fields:    Translation:AnimalsCells
    99. Williams LD, Ofek G, Schätzle S, McDaniel JR, Lu X, Nicely NI, Wu L, Lougheed CS, Bradley T, Louder MK, McKee K, Bailer RT, O'Dell S, Georgiev IS, Seaman MS, Parks RJ, Marshall DJ, Anasti K, Yang G, Nie X, Tumba NL, Wiehe K, Wagh K, Korber B, Kepler TB, Munir Alam S, Morris L, Kamanga G, Cohen MS, Bonsignori M, Xia SM, Montefiori DC, Kelsoe G, Gao F, Mascola JR, Moody MA, Saunders KO, Liao HX, Tomaras GD, Georgiou G, Haynes BF. Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Sci Immunol. 2017 Jan 27; 2(7). PMID: 28783671; PMCID: PMC5905719.
      Citations: 73     Fields:    
    100. Wibmer CK, Gorman J, Ozorowski G, Bhiman JN, Sheward DJ, Elliott DH, Rouelle J, Smira A, Joyce MG, Ndabambi N, Druz A, Asokan M, Burton DR, Connors M, Abdool Karim SS, Mascola JR, Robinson JE, Ward AB, Williamson C, Kwong PD, Morris L, Moore PL. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathog. 2017 01; 13(1):e1006074. PMID: 28076415; PMCID: PMC5226681.
      Citations: 23     Fields:    Translation:HumansCells
    101. Doria-Rose NA, Altae-Tran HR, Roark RS, Schmidt SD, Sutton MS, Louder MK, Chuang GY, Bailer RT, Cortez V, Kong R, McKee K, O'Dell S, Wang F, Abdool Karim SS, Binley JM, Connors M, Haynes BF, Martin MA, Montefiori DC, Morris L, Overbaugh J, Kwong PD, Mascola JR, Georgiev IS. Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. PLoS Pathog. 2017 01; 13(1):e1006148. PMID: 28052137; PMCID: PMC5241146.
      Citations: 37     Fields:    Translation:HumansCells
    102. Moore PL, Gorman J, Doria-Rose NA, Morris L. Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies. Immunol Rev. 2017 01; 275(1):217-229. PMID: 28133797; PMCID: PMC5300058.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    103. Sacks D, Ledwaba J, Morris L, Hunt GM. Rapid Detection of Common HIV-1 Drug Resistance Mutations by Use of High-Resolution Melting Analysis and Unlabeled Probes. J Clin Microbiol. 2017 01; 55(1):122-133. PMID: 27795333; PMCID: PMC5228223.
      Citations: 7     Fields:    Translation:HumansCells
    104. Wibmer CK, Gorman J, Anthony CS, Mkhize NN, Druz A, York T, Schmidt SD, Labuschagne P, Louder MK, Bailer RT, Abdool Karim SS, Mascola JR, Williamson C, Moore PL, Kwong PD, Morris L. Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site. J Virol. 2016 Nov 15; 90(22):10220-10235. PMID: 27581986; PMCID: PMC5105658.
      Citations: 24     Fields:    Translation:HumansCells
    105. Muenchhoff M, Adland E, Karimanzira O, Crowther C, Pace M, Csala A, Leitman E, Moonsamy A, McGregor C, Hurst J, Groll A, Mori M, Sinmyee S, Thobakgale C, Tudor-Williams G, Prendergast AJ, Kloverpris H, Roider J, Leslie A, Shingadia D, Brits T, Daniels S, Frater J, Willberg CB, Walker BD, Ndung'u T, Jooste P, Moore PL, Morris L, Goulder P. Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection. Sci Transl Med. 2016 09 28; 8(358):358ra125. PMID: 27683550; PMCID: PMC6087524.
      Citations: 77     Fields:    Translation:HumansAnimalsCells
    106. Churchyard G, Mlisana K, Karuna S, Williamson AL, Williamson C, Morris L, Tomaras GD, De Rosa SC, Gilbert PB, Gu N, Yu C, Mkhize NN, Hermanus T, Allen M, Pensiero M, Barnett SW, Gray G, Bekker LG, Montefiori DC, Kublin J, Corey L. Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. PLoS One. 2016; 11(9):e0161753. PMID: 27583368; PMCID: PMC5008759.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    107. Bradley T, Trama A, Tumba N, Gray E, Lu X, Madani N, Jahanbakhsh F, Eaton A, Xia SM, Parks R, Lloyd KE, Sutherland LL, Scearce RM, Bowman CM, Barnett S, Abdool-Karim SS, Boyd SD, Melillo B, Smith AB, Sodroski J, Kepler TB, Alam SM, Gao F, Bonsignori M, Liao HX, Moody MA, Montefiori D, Santra S, Morris L, Haynes BF. Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. EBioMedicine. 2016 Oct; 12:196-207. PMID: 27612593; PMCID: PMC5078591.
      Citations: 26     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    108. Deshpande S, Patil S, Kumar R, Hermanus T, Murugavel KG, Srikrishnan AK, Solomon S, Morris L, Bhattacharya J. HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms. Retrovirology. 2016 08 30; 13(1):60. PMID: 27576440; PMCID: PMC5006590.
      Citations: 11     Fields:    Translation:HumansCells
    109. Rademeyer C, Korber B, Seaman MS, Giorgi EE, Thebus R, Robles A, Sheward DJ, Wagh K, Garrity J, Carey BR, Gao H, Greene KM, Tang H, Bandawe GP, Marais JC, Diphoko TE, Hraber P, Tumba N, Moore PL, Gray GE, Kublin J, McElrath MJ, Vermeulen M, Middelkoop K, Bekker LG, Hoelscher M, Maboko L, Makhema J, Robb ML, Abdool Karim S, Abdool Karim Q, Kim JH, Hahn BH, Gao F, Swanstrom R, Morris L, Montefiori DC, Williamson C. Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. PLoS Pathog. 2016 07; 12(7):e1005742. PMID: 27434311; PMCID: PMC4951126.
      Citations: 63     Fields:    Translation:HumansCellsPHPublic Health
    110. Mufhandu HT, Alexandre KB, Gray ES, Morris L, Khati M. UCLA1 aptamer inhibition of human immunodeficiency virus type 1 subtype C primary isolates in macrophages and selection of resistance. Biochem Biophys Rep. 2016 Sep; 7:408-414. PMID: 28955932; PMCID: PMC5613508.
      Citations: 1     
    111. Gray GE, Mayer KH, Elizaga ML, Bekker LG, Allen M, Morris L, Montefiori D, De Rosa SC, Sato A, Gu N, Tomaras GD, Tucker T, Barnett SW, Mkhize NN, Shen X, Downing K, Williamson C, Pensiero M, Corey L, Williamson AL. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. Clin Vaccine Immunol. 2016 06; 23(6):496-506. PMID: 27098021; PMCID: PMC4895009.
      Citations: 18     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    112. Sheng Z, Schramm CA, Connors M, Morris L, Mascola JR, Kwong PD, Shapiro L. Effects of Darwinian Selection and Mutability on Rate of Broadly Neutralizing Antibody Evolution during HIV-1 Infection. PLoS Comput Biol. 2016 05; 12(5):e1004940. PMID: 27191167; PMCID: PMC4871536.
      Citations: 27     Fields:    Translation:HumansCells
    113. Mkhize NN, Durgiah R, Ashley V, Archary D, Garrett NJ, Karim QA, Karim SS, Moore PL, Yates N, Passmore JA, Tomaras GD, Morris L. Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. AIDS. 2016 Apr 24; 30(7):1005-14. PMID: 26836790; PMCID: PMC4816677.
      Citations: 15     Fields:    Translation:HumansCells
    114. Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, Garrity J, Rist M, Rademeyer C, Yoon H, Lapedes A, Gao H, Greene K, Louder MK, Kong R, Karim SA, Burton DR, Barouch DH, Nussenzweig MC, Mascola JR, Morris L, Montefiori DC, Korber B, Seaman MS. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathog. 2016 Mar; 12(3):e1005520. PMID: 27028935; PMCID: PMC4814126.
      Citations: 117     Fields:    Translation:HumansCells
    115. Giandhari J, Basson AE, Sutherland K, Parry CM, Cane PA, Coovadia A, Kuhn L, Hunt G, Morris L. Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy. Antimicrob Agents Chemother. 2016 Apr; 60(4):2248-56. PMID: 26833162; PMCID: PMC4808165.
      Citations: 6     Fields:    Translation:HumansCells
    116. Bradley T, Fera D, Bhiman J, Eslamizar L, Lu X, Anasti K, Zhang R, Sutherland LL, Scearce RM, Bowman CM, Stolarchuk C, Lloyd KE, Parks R, Eaton A, Foulger A, Nie X, Karim SSA, Barnett S, Kelsoe G, Kepler TB, Alam SM, Montefiori DC, Moody MA, Liao HX, Morris L, Santra S, Harrison SC, Haynes BF. Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. Cell Rep. 2016 Jan 05; 14(1):43-54. PMID: 26725118; PMCID: PMC4706810.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    117. Gorman J, Soto C, Yang MM, Davenport TM, Guttman M, Bailer RT, Chambers M, Chuang GY, DeKosky BJ, Doria-Rose NA, Druz A, Ernandes MJ, Georgiev IS, Jarosinski MC, Joyce MG, Lemmin TM, Leung S, Louder MK, McDaniel JR, Narpala S, Pancera M, Stuckey J, Wu X, Yang Y, Zhang B, Zhou T, NISC Comparative Sequencing Program, Mullikin JC, Baxa U, Georgiou G, McDermott AB, Bonsignori M, Haynes BF, Moore PL, Morris L, Lee KK, Shapiro L, Mascola JR, Kwong PD. Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nat Struct Mol Biol. 2016 Jan; 23(1):81-90. PMID: 26689967; PMCID: PMC4833398.
      Citations: 108     Fields:    Translation:HumansCells
    118. Doria-Rose NA, Bhiman JN, Roark RS, Schramm CA, Gorman J, Chuang GY, Pancera M, Cale EM, Ernandes MJ, Louder MK, Asokan M, Bailer RT, Druz A, Fraschilla IR, Garrett NJ, Jarosinski M, Lynch RM, McKee K, O'Dell S, Pegu A, Schmidt SD, Staupe RP, Sutton MS, Wang K, Wibmer CK, Haynes BF, Abdool-Karim S, Shapiro L, Kwong PD, Moore PL, Morris L, Mascola JR. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. J Virol. 2016 01 01; 90(1):76-91. PMID: 26468542; PMCID: PMC4702551.
      Citations: 160     Fields:    Translation:HumansCells
    119. Bhiman JN, Anthony C, Doria-Rose NA, Karimanzira O, Schramm CA, Khoza T, Kitchin D, Botha G, Gorman J, Garrett NJ, Abdool Karim SS, Shapiro L, Williamson C, Kwong PD, Mascola JR, Morris L, Moore PL. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat Med. 2015 Nov; 21(11):1332-6. PMID: 26457756; PMCID: PMC4637988.
      Citations: 140     Fields:    Translation:HumansCells
    120. Moody MA, Gao F, Gurley TC, Amos JD, Kumar A, Hora B, Marshall DJ, Whitesides JF, Xia SM, Parks R, Lloyd KE, Hwang KK, Lu X, Bonsignori M, Finzi A, Vandergrift NA, Alam SM, Ferrari G, Shen X, Tomaras GD, Kamanga G, Cohen MS, Sam NE, Kapiga S, Gray ES, Tumba NL, Morris L, Zolla-Pazner S, Gorny MK, Mascola JR, Hahn BH, Shaw GM, Sodroski JG, Liao HX, Montefiori DC, Hraber PT, Korber BT, Haynes BF. Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host Microbe. 2015 Sep 09; 18(3):354-62. PMID: 26355218; PMCID: PMC4567706.
      Citations: 50     Fields:    Translation:Cells
    121. Salimo AT, Ledwaba J, Coovadia A, Abrams EJ, Technau KG, Kuhn L, Morris L, Hunt GM. The use of dried blood spot specimens for HIV-1 drug resistance genotyping in young children initiating antiretroviral therapy. J Virol Methods. 2015 Oct; 223:30-2. PMID: 26192603; PMCID: PMC4561412.
      Citations: 5     Fields:    Translation:HumansCells
    122. Archary D, Liebenberg LJ, Werner L, Tulsi S, Majola N, Naicker N, Dlamini S, Hope TJ, Samsunder N, Abdool Karim SS, Morris L, Passmore JA, Garrett NJ. Randomized Cross-Sectional Study to Compare HIV-1 Specific Antibody and Cytokine Concentrations in Female Genital Secretions Obtained by Menstrual Cup and Cervicovaginal Lavage. PLoS One. 2015; 10(7):e0131906. PMID: 26147923; PMCID: PMC4492781.
      Citations: 19     Fields:    Translation:HumansCells
    123. Richardson SI, Gray ES, Mkhize NN, Sheward DJ, Lambson BE, Wibmer CK, Masson L, Werner L, Garrett N, Passmore JA, Karim QA, Karim SS, Williamson C, Moore PL, Morris L. South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on a4ß7 for replication. Retrovirology. 2015 Jun 24; 12:54. PMID: 26105197; PMCID: PMC4479312.
      Citations: 12     Fields:    Translation:HumansCells
    124. Giandhari J, Basson AE, Coovadia A, Kuhn L, Abrams EJ, Strehlau R, Morris L, Hunt GM. Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients. AIDS Res Hum Retroviruses. 2015 Aug; 31(8):776-82. PMID: 25919760; PMCID: PMC4533029.
      Citations: 9     Fields:    Translation:HumansCells
    125. Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Kee PN, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HM, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, Vandamme AM, Shafer RW. Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. PLoS Med. 2015 Jun; 12(6):e1001845. PMID: 26030872; PMCID: PMC4452696.
      Citations: 4     Fields:    
    126. Payne H, Mkhize N, Otwombe K, Lewis J, Panchia R, Callard R, Morris L, Babiker A, Violari A, Cotton MF, Klein NJ, Gibb DM. Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis. Lancet Infect Dis. 2015 Jul; 15(7):803-9. PMID: 26043884; PMCID: PMC4529673.
      Citations: 29     Fields:    Translation:HumansCellsCTClinical Trials
    127. Wibmer CK, Moore PL, Morris L. HIV broadly neutralizing antibody targets. Curr Opin HIV AIDS. 2015 May; 10(3):135-43. PMID: 25760932; PMCID: PMC4437463.
      Citations: 92     Fields:    Translation:HumansCells
    128. Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, Rinke de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Ng KP, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HM, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, Vandamme AM, Shafer RW. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med. 2015 Apr; 12(4):e1001810. PMID: 25849352; PMCID: PMC4388826.
      Citations: 118     Fields:    Translation:HumansCells
    129. Hong SY, Jonas A, DeKlerk M, Shiningavamwe A, Desta T, Badi A, Morris L, Hunt GM, Ledwaba J, Sheehan HB, Lau K, Trotter A, Tang AM, Wanke C, Jordan MR. Population-based surveillance of HIV drug resistance emerging on treatment and associated factors at sentinel antiretroviral therapy sites in Namibia. J Acquir Immune Defic Syndr. 2015 Apr 01; 68(4):463-71. PMID: 25564107; PMCID: PMC4334707.
      Citations: 10     Fields:    Translation:HumansCellsPHPublic Health
    130. Scheepers C, Shrestha RK, Lambson BE, Jackson KJ, Wright IA, Naicker D, Goosen M, Berrie L, Ismail A, Garrett N, Abdool Karim Q, Abdool Karim SS, Moore PL, Travers SA, Morris L. Ability to develop broadly neutralizing HIV-1 antibodies is not restricted by the germline Ig gene repertoire. J Immunol. 2015 May 01; 194(9):4371-8. PMID: 25825450; PMCID: PMC4513073.
      Citations: 41     Fields:    Translation:HumansCells
    131. Moore PL, Williamson C, Morris L. Virological features associated with the development of broadly neutralizing antibodies to HIV-1. Trends Microbiol. 2015 Apr; 23(4):204-11. PMID: 25572881; PMCID: PMC4380704.
      Citations: 54     Fields:    Translation:HumansCells
    132. Garrett NJ, Werner L, Naicker N, Naranbhai V, Sibeko S, Samsunder N, Gray C, Williamson C, Morris L, Abdool-Karim Q, Abdool-Karim SS. HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial. J Acquir Immune Defic Syndr. 2015 Jan 01; 68(1):55-61. PMID: 25247433; PMCID: PMC4262710.
      Citations: 10     Fields:    Translation:HumansPHPublic Health
    133. Wiehe K, Easterhoff D, Luo K, Nicely NI, Bradley T, Jaeger FH, Dennison SM, Zhang R, Lloyd KE, Stolarchuk C, Parks R, Sutherland LL, Scearce RM, Morris L, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Sinangil F, Phogat S, Michael NL, Kim JH, Kelsoe G, Montefiori DC, Tomaras GD, Bonsignori M, Santra S, Kepler TB, Alam SM, Moody MA, Liao HX, Haynes BF. Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. Immunity. 2014 Dec 18; 41(6):909-18. PMID: 25526306; PMCID: PMC4324565.
      Citations: 47     Fields:    Translation:HumansAnimalsCells
    134. Basson AE, Rhee SY, Parry CM, El-Khatib Z, Charalambous S, De Oliveira T, Pillay D, Hoffmann C, Katzenstein D, Shafer RW, Morris L. Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2015 Feb; 59(2):960-71. PMID: 25421485; PMCID: PMC4335849.
      Citations: 32     Fields:    Translation:HumansCells
    135. Bandawe GP, Moore PL, Werner L, Gray ES, Sheward DJ, Madiga M, Nofemela A, Thebus R, Marais JC, Maboko L, Abdool Karim SS, Hoelscher M, Morris L, Williamson C. Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa. J Infect Dis. 2015 May 01; 211(9):1461-6. PMID: 25398460; PMCID: PMC4462656.
      Citations: 4     Fields:    Translation:HumansCells
    136. Lopes de Campos WR, Chirwa N, London G, Rotherham LS, Morris L, Mayosi BM, Khati M. HIV-1 subtype C unproductively infects human cardiomyocytes in vitro and induces apoptosis mitigated by an anti-Gp120 aptamer. PLoS One. 2014; 9(10):e110930. PMID: 25329893; PMCID: PMC4201581.
      Citations: 12     Fields:    Translation:HumansCells
    137. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J, Huang J, Acharya P, Chuang GY, Ofek G, Stewart-Jones GB, Stuckey J, Bailer RT, Joyce MG, Louder MK, Tumba N, Yang Y, Zhang B, Cohen MS, Haynes BF, Mascola JR, Morris L, Munro JB, Blanchard SC, Mothes W, Connors M, Kwong PD. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature. 2014 Oct 23; 514(7523):455-61. PMID: 25296255; PMCID: PMC4348022.
      Citations: 501     Fields:    Translation:HumansCells
    138. Kepler TB, Liao HX, Alam SM, Bhaskarabhatla R, Zhang R, Yandava C, Stewart S, Anasti K, Kelsoe G, Parks R, Lloyd KE, Stolarchuk C, Pritchett J, Solomon E, Friberg E, Morris L, Karim SS, Cohen MS, Walter E, Moody MA, Wu X, Altae-Tran HR, Georgiev IS, Kwong PD, Boyd SD, Fire AZ, Mascola JR, Haynes BF. Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. Cell Host Microbe. 2014 Sep 10; 16(3):304-13. PMID: 25211073; PMCID: PMC4163498.
      Citations: 94     Fields:    Translation:HumansCells
    139. Lai RP, Hock M, Radzimanowski J, Tonks P, Hulsik DL, Effantin G, Seilly DJ, Dreja H, Kliche A, Wagner R, Barnett SW, Tumba N, Morris L, LaBranche CC, Montefiori DC, Seaman MS, Heeney JL, Weissenhorn W. A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1. J Biol Chem. 2014 Oct 24; 289(43):29912-26. PMID: 25160627; PMCID: PMC4208001.
      Citations: 20     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    140. Müller R, Mulani I, Basson AE, Pribut N, Hassam M, Morris L, van Otterlo WAL, Pelly SC. Novel indole based NNRTIs with improved potency against wild type and resistant HIV. Bioorg Med Chem Lett. 2014 Sep 15; 24(18):4376-4380. PMID: 25176191.
      Citations: 2     Fields:    Translation:Cells
    141. Trama AM, Moody MA, Alam SM, Jaeger FH, Lockwood B, Parks R, Lloyd KE, Stolarchuk C, Scearce R, Foulger A, Marshall DJ, Whitesides JF, Jeffries TL, Wiehe K, Morris L, Lambson B, Soderberg K, Hwang KK, Tomaras GD, Vandergrift N, Jackson KJL, Roskin KM, Boyd SD, Kepler TB, Liao HX, Haynes BF. HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. Cell Host Microbe. 2014 Aug 13; 16(2):215-226. PMID: 25121750; PMCID: PMC4294419.
      Citations: 71     Fields:    Translation:HumansCells
    142. Mlisana K, Werner L, Garrett NJ, McKinnon LR, van Loggerenberg F, Passmore JA, Gray CM, Morris L, Williamson C, Abdool Karim SS, Centre for the AIDS Programme of Research in South Africa (CAPRISA) 002 Study Team. Rapid disease progression in HIV-1 subtype C-infected South African women. Clin Infect Dis. 2014 Nov 01; 59(9):1322-31. PMID: 25038116; PMCID: PMC4271037.
      Citations: 26     Fields:    Translation:HumansCells
    143. Kuhn L, Hunt G, Technau KG, Coovadia A, Ledwaba J, Pickerill S, Penazzato M, Bertagnolio S, Mellins CA, Black V, Morris L, Abrams EJ. Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis. AIDS. 2014 Jul 17; 28(11):1673-8. PMID: 24785949; PMCID: PMC4539942.
      Citations: 44     Fields:    Translation:HumansCells
    144. Mosha F, Ledwaba J, Ndugulile F, Ng'ang'a Z, Nsubuga P, Morris L, Kasubi M, Swai A, Vercauteren J, Vandamme AM. Clinical and virological response to antiretroviral drugs among HIV patients on first-line treatment in Dar-es-Salaam, Tanzania. J Infect Dev Ctries. 2014 Jul 14; 8(7):845-52. PMID: 25022294.
      Citations: 4     Fields:    Translation:HumansCells
    145. Hunt GM, Morris L, Moorthy A, Coovadia A, Abrams EJ, Strehlau R, Kuhn L, Persaud D. Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. J Virol Methods. 2014 Oct; 207:182-7. PMID: 25034127; PMCID: PMC4150030.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    146. Derdeyn CA, Moore PL, Morris L. Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection. Curr Opin HIV AIDS. 2014 May; 9(3):210-6. PMID: 24662931; PMCID: PMC4068799.
      Citations: 50     Fields:    Translation:Humans
    147. Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z, NISC Comparative Sequencing Program, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, Abdool Karim SS, Morris L, Kwong PD, Shapiro L, Mascola JR. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014 May 01; 509(7498):55-62. PMID: 24590074; PMCID: PMC4395007.
      Citations: 472     Fields:    Translation:HumansCells
    148. Brown GD, Meintjes G, Kolls JK, Gray C, Horsnell W, Working Group from the EMBO-AIDS Related Mycoses Workshop, Achan B, Alber G, Aloisi M, Armstrong-James D, Beale M, Bicanic T, Black J, Bohjanen P, Botes A, Boulware DR, Brown G, Bunjun R, Carr W, Casadevall A, Chang C, Chivero E, Corcoran C, Cross A, Dawood H, Day J, De Bernardis F, De Jager V, De Repentigny L, Denning D, Eschke M, Finkelman M, Govender N, Gow N, Graham L, Gryschek R, Hammond-Aryee K, Harrison T, Heard N, Hill M, Hoving JC, Janoff E, Jarvis J, Kayuni S, King K, Kolls J, Kullberg BJ, Lalloo DG, Letang E, Levitz S, Limper A, Longley N, Machiridza TR, Mahabeer Y, Martinsons N, Meiring S, Meya D, Miller R, Molloy S, Morris L, Mukaremera L, Musubire AK, Muzoora C, Nair A, Nakiwala Kimbowa J, Netea M, Nielsen K, O'hern J, Okurut S, Parker A, Patterson T, Pennap G, Perfect J, Prinsloo C, Rhein J, Rolfes MA, Samuel C, Schutz C, Scriven J, Sebolai OM, Sojane K, Sriruttan C, Stead D, Steyn A, Thawer NK, Thienemann F, Von Hohenberg M, Vreulink JM, Wessels J, Wood K, Yang YL. AIDS-related mycoses: the way forward. Trends Microbiol. 2014 Mar; 22(3):107-9. PMID: 24581941; PMCID: PMC4129449.
      Citations: 11     Fields:    Translation:Humans
    149. Hoffmann CJ, Charalambous S, Grant AD, Morris L, Churchyard GJ, Chaisson RE. Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study. Trop Med Int Health. 2014 Feb; 19(2):236-9. PMID: 24588012; PMCID: PMC4070658.
      Citations: 9     Fields:    Translation:HumansCells
    150. Wei X, Hunt G, Abdool Karim SS, Naranbhai V, Sibeko S, Abdool Karim Q, Li JF, Kashuba AD, Werner L, Passmore JA, Morris L, Heneine W, Johnson JA. Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial. J Infect Dis. 2014 Jun 15; 209(12):1916-20. PMID: 24436453; PMCID: PMC4038144.
      Citations: 7     Fields:    Translation:HumansCells
    151. Lacerda M, Moore PL, Ngandu NK, Seaman M, Gray ES, Murrell B, Krishnamoorthy M, Nonyane M, Madiga M, Wibmer CK, Sheward D, Bailer RT, Gao H, Greene KM, Karim SS, Mascola JR, Korber BT, Montefiori DC, Morris L, Williamson C, Seoighe C, CAVD-NSDP Consortium. Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. Virol J. 2013 Dec 02; 10:347. PMID: 24295501; PMCID: PMC4220805.
      Citations: 11     Fields:    Translation:Cells
    152. Wibmer CK, Bhiman JN, Gray ES, Tumba N, Abdool Karim SS, Williamson C, Morris L, Moore PL. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog. 2013 Oct; 9(10):e1003738. PMID: 24204277; PMCID: PMC3814426.
      Citations: 132     Fields:    Translation:HumansCellsCTClinical Trials
    153. Alexandre KB, Moore PL, Nonyane M, Gray ES, Ranchobe N, Chakauya E, McMahon JB, O'Keefe BR, Chikwamba R, Morris L. Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN. Virology. 2013 Nov; 446(1-2):66-76. PMID: 24074568; PMCID: PMC3787538.
      Citations: 19     Fields:    Translation:HumansCells
    154. Johnston V, Cohen K, Wiesner L, Morris L, Ledwaba J, Fielding KL, Charalambous S, Churchyard G, Phillips A, Grant AD. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. J Infect Dis. 2014 Mar 01; 209(5):711-20. PMID: 23943851; PMCID: PMC3923537.
      Citations: 34     Fields:    Translation:HumansCells
    155. Hoffmann CJ, Ledwaba J, Li JF, Johnston V, Hunt G, Fielding KL, Chaisson RE, Churchyard GJ, Grant AD, Johnson JA, Charalambous S, Morris L. Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. Antivir Ther. 2013; 18(7):915-20. PMID: 23751421; PMCID: PMC4046272.
      Citations: 14     Fields:    Translation:HumansCells
    156. Georgiev IS, Doria-Rose NA, Zhou T, Kwon YD, Staupe RP, Moquin S, Chuang GY, Louder MK, Schmidt SD, Altae-Tran HR, Bailer RT, McKee K, Nason M, O'Dell S, Ofek G, Pancera M, Srivatsan S, Shapiro L, Connors M, Migueles SA, Morris L, Nishimura Y, Martin MA, Mascola JR, Kwong PD. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science. 2013 May 10; 340(6133):751-6. PMID: 23661761.
      Citations: 144     Fields:    Translation:HumansAnimalsCells
    157. Ping LH, Joseph SB, Anderson JA, Abrahams MR, Salazar-Gonzalez JF, Kincer LP, Treurnicht FK, Arney L, Ojeda S, Zhang M, Keys J, Potter EL, Chu H, Moore P, Salazar MG, Iyer S, Jabara C, Kirchherr J, Mapanje C, Ngandu N, Seoighe C, Hoffman I, Gao F, Tang Y, Labranche C, Lee B, Saville A, Vermeulen M, Fiscus S, Morris L, Karim SA, Haynes BF, Shaw GM, Korber BT, Hahn BH, Cohen MS, Montefiori D, Williamson C, Swanstrom R, CAPRISA Acute Infection Study and the Center for HIV-AIDS Vaccine Immunology Consortium. Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. J Virol. 2013 Jul; 87(13):7218-33. PMID: 23616655; PMCID: PMC3700278.
      Citations: 72     Fields:    Translation:HumansCells
    158. Andersson E, Shao W, Bontell I, Cham F, Cuong do D, Wondwossen A, Morris L, Hunt G, Sönnerborg A, Bertagnolio S, Maldarelli F, Jordan MR. Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. Infect Genet Evol. 2013 Aug; 18:125-31. PMID: 23583545; PMCID: PMC4066879.
      Citations: 42     Fields:    Translation:HumansCells
    159. Moore PL, Sheward D, Nonyane M, Ranchobe N, Hermanus T, Gray ES, Abdool Karim SS, Williamson C, Morris L. Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. J Virol. 2013 May; 87(9):4882-94. PMID: 23408621; PMCID: PMC3624332.
      Citations: 47     Fields:    Translation:HumansCells
    160. Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, Hermanus T, Bajimaya S, Tumba NL, Abrahams MR, Lambson BE, Ranchobe N, Ping L, Ngandu N, Abdool Karim Q, Abdool Karim SS, Swanstrom RI, Seaman MS, Williamson C, Morris L. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 2012 Nov; 18(11):1688-92. PMID: 23086475; PMCID: PMC3494733.
      Citations: 194     Fields:    Translation:HumansCells
    161. Archary D, Rong R, Gordon ML, Boliar S, Madiga M, Gray ES, Dugast AS, Hermanus T, Goulder PJ, Coovadia HM, Werner L, Morris L, Alter G, Derdeyn CA, Ndung'u T. Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. Virology. 2012 Nov 25; 433(2):410-20. PMID: 22995189; PMCID: PMC3488441.
      Citations: 3     Fields:    Translation:HumansCells
    162. Klein F, Gaebler C, Mouquet H, Sather DN, Lehmann C, Scheid JF, Kraft Z, Liu Y, Pietzsch J, Hurley A, Poignard P, Feizi T, Morris L, Walker BD, Fätkenheuer G, Seaman MS, Stamatatos L, Nussenzweig MC. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med. 2012 Jul 30; 209(8):1469-79. PMID: 22826297; PMCID: PMC3409500.
      Citations: 110     Fields:    Translation:HumansCells
    163. Lynch RM, Tran L, Louder MK, Schmidt SD, Cohen M, CHAVI 001 Clinical Team Members, Dersimonian R, Euler Z, Gray ES, Abdool Karim S, Kirchherr J, Montefiori DC, Sibeko S, Soderberg K, Tomaras G, Yang ZY, Nabel GJ, Schuitemaker H, Morris L, Haynes BF, Mascola JR. The development of CD4 binding site antibodies during HIV-1 infection. J Virol. 2012 Jul; 86(14):7588-95. PMID: 22573869; PMCID: PMC3416294.
      Citations: 90     Fields:    Translation:HumansCells
    164. Heyndrickx L, Heath A, Sheik-Khalil E, Alcami J, Bongertz V, Jansson M, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Ramaswamy M, Sattentau Q, Tolazzi M, Schuitemaker H, Willems B, Wrin T, Fenyö EM, Scarlatti G. International network for comparison of HIV neutralization assays: the NeutNet report II. PLoS One. 2012; 7(5):e36438. PMID: 22590544; PMCID: PMC3348930.
      Citations: 31     Fields:    Translation:HumansCellsCTClinical Trials
    165. Hassam M, Basson AE, Liotta DC, Morris L, van Otterlo WA, Pelly SC. Novel Cyclopropyl-Indole Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors. ACS Med Chem Lett. 2012 Jun 14; 3(6):470-5. PMID: 24900496; PMCID: PMC4025642.
      Citations: 9     
    166. Kuhn L, Coovadia A, Strehlau R, Martens L, Hu CC, Meyers T, Sherman G, Hunt G, Persaud D, Morris L, Tsai WY, Abrams EJ. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. 2012 Jul; 12(7):521-30. PMID: 22424722; PMCID: PMC4539971.
      Citations: 38     Fields:    Translation:Humans
    167. Mufhandu HT, Gray ES, Madiga MC, Tumba N, Alexandre KB, Khoza T, Wibmer CK, Moore PL, Morris L, Khati M. UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C. J Virol. 2012 May; 86(9):4989-99. PMID: 22379083; PMCID: PMC3347371.
      Citations: 19     Fields:    Translation:HumansCells
    168. Overbaugh J, Morris L. The Antibody Response against HIV-1. Cold Spring Harb Perspect Med. 2012 Jan; 2(1):a007039. PMID: 22315717; PMCID: PMC3253031.
      Citations: 105     Fields:    Translation:HumansCells
    169. Alexandre KB, Gray ES, Mufhandu H, McMahon JB, Chakauya E, O'Keefe BR, Chikwamba R, Morris L. The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells. Virology. 2012 Feb 20; 423(2):175-86. PMID: 22209231; PMCID: PMC3274779.
      Citations: 28     Fields:    Translation:HumansCells
    170. Dlamini JN, Hu Z, Ledwaba J, Morris L, Maldarelli FM, Dewar RL, Highbarger HC, Somaroo H, Sangweni P, Follmann DA, Pau AK, Phidisa II Study Team. Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):304-8. PMID: 21694608; PMCID: PMC3197956.
      Citations: 5     Fields:    Translation:Humans
    171. Morris L, Chen X, Alam M, Tomaras G, Zhang R, Marshall DJ, Chen B, Parks R, Foulger A, Jaeger F, Donathan M, Bilska M, Gray ES, Abdool Karim SS, Kepler TB, Whitesides J, Montefiori D, Moody MA, Liao HX, Haynes BF. Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One. 2011; 6(9):e23532. PMID: 21980336; PMCID: PMC3184076.
      Citations: 107     Fields:    Translation:HumansCells
    172. Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, Moore PL, Tumba N, Tong T, Shen X, Yates NL, Decker J, Wibmer CK, Gao F, Alam SM, Easterbrook P, Abdool Karim S, Kamanga G, Crump JA, Cohen M, Shaw GM, Mascola JR, Haynes BF, Montefiori DC, Morris L. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol. 2011 Nov; 85(21):11502-19. PMID: 21849452; PMCID: PMC3194956.
      Citations: 134     Fields:    Translation:HumansCells
    173. Hunt GM, Coovadia A, Abrams EJ, Sherman G, Meyers T, Morris L, Kuhn L. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS. 2011 Jul 31; 25(12):1461-9. PMID: 21633285; PMCID: PMC4547386.
      Citations: 29     Fields:    Translation:HumansCellsPHPublic Health
    174. Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, Marshall DJ, Crump JA, Kapiga SH, Sam NE, Sinangil F, Pancera M, Yongping Y, Zhang B, Zhu J, Kwong PD, O'Dell S, Mascola JR, Wu L, Nabel GJ, Phogat S, Seaman MS, Whitesides JF, Moody MA, Kelsoe G, Yang X, Sodroski J, Shaw GM, Montefiori DC, Kepler TB, Tomaras GD, Alam SM, Liao HX, Haynes BF. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol. 2011 Oct; 85(19):9998-10009. PMID: 21795340; PMCID: PMC3196428.
      Citations: 286     Fields:    Translation:HumansCells
    175. Firnhaber C, Azzoni L, Foulkes AS, Gross R, Yin X, Van Amsterdam D, Schulze D, Glencross DK, Stevens W, Hunt G, Morris L, Fox L, Sanne I, Montaner LJ. Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection. PLoS One. 2011; 6(6):e21450. PMID: 21738668; PMCID: PMC3125169.
      Citations: 3     Fields:    Translation:Cells
    176. Alexandre KB, Gray ES, Pantophlet R, Moore PL, McMahon JB, Chakauya E, O'Keefe BR, Chikwamba R, Morris L. Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. J Virol. 2011 Sep; 85(17):9039-50. PMID: 21697467; PMCID: PMC3165825.
      Citations: 39     Fields:    Translation:HumansCells
    177. Gray ES, Moody MA, Wibmer CK, Chen X, Marshall D, Amos J, Moore PL, Foulger A, Yu JS, Lambson B, Abdool Karim S, Whitesides J, Tomaras GD, Haynes BF, Morris L, Liao HX. Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. J Virol. 2011 Aug; 85(15):7719-29. PMID: 21613396; PMCID: PMC3147894.
      Citations: 42     Fields:    Translation:HumansCells
    178. Taylor BS, Hunt G, Abrams EJ, Coovadia A, Meyers T, Sherman G, Strehlau R, Morris L, Kuhn L. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses. 2011 Sep; 27(9):945-56. PMID: 21345162; PMCID: PMC3161115.
      Citations: 16     Fields:    Translation:HumansCells
    179. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, Werner L, Mlisana K, Sibeko S, Williamson C, Abdool Karim SS, Morris L, CAPRISA002 Study Team. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol. 2011 May; 85(10):4828-40. PMID: 21389135; PMCID: PMC3126191.
      Citations: 303     Fields:    Translation:HumansCells
    180. El-Khatib Z, Katzenstein D, Marrone G, Laher F, Mohapi L, Petzold M, Morris L, Ekström AM. Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One. 2011 Mar 09; 6(3):e17518. PMID: 21408071; PMCID: PMC3052314.
      Citations: 63     Fields:    Translation:Humans
    181. El-Khatib Z, Delong AK, Katzenstein D, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, Petzold M, Morris L, Kantor R. Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa. J AIDS Clin Res. 2011 Feb 18; 2(117). PMID: 21927716; PMCID: PMC3174802.
      Citations: 17     
    182. El-Khatib Z, Ekstrom AM, Coovadia A, Abrams EJ, Petzold M, Katzenstein D, Morris L, Kuhn L. Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study. BMC Public Health. 2011 Feb 08; 11:88. PMID: 21303548; PMCID: PMC3046911.
      Citations: 46     Fields:    Translation:HumansCells
    183. Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, Abdool Karim SS, Williamson C, Pinter A, Morris L, CAPRISA 002 Study. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol. 2011 Apr; 85(7):3128-41. PMID: 21270156; PMCID: PMC3067856.
      Citations: 112     Fields:    Translation:HumansCells
    184. Li JF, Lipscomb JT, Wei X, Martinson NA, Morris L, Heneine W, Johnson JA. Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections. J Infect Dis. 2011 Mar 15; 203(6):798-802. PMID: 21257741; PMCID: PMC3071134.
      Citations: 14     Fields:    Translation:HumansCellsPHPublic Health
    185. Coetzer M, Nedellec R, Cilliers T, Meyers T, Morris L, Mosier DE. Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C. J Acquir Immune Defic Syndr. 2011 Jan 01; 56(1):9-15. PMID: 20921899; PMCID: PMC3006070.
      Citations: 18     Fields:    Translation:HumansCells
    186. Coovadia A, Abrams EJ, Stehlau R, Meyers T, Martens L, Sherman G, Hunt G, Hu CC, Tsai WY, Morris L, Kuhn L. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA. 2010 Sep 08; 304(10):1082-90. PMID: 20823434; PMCID: PMC4540068.
      Citations: 51     Fields:    Translation:HumansCellsPHPublic Health
    187. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010 Sep 03; 329(5996):1168-74. PMID: 20643915; PMCID: PMC3001187.
      Citations: 1245     Fields:    Translation:HumansCells
    188. El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, Karstaedt A, Charalambous S, Petzold M, Katzenstein D, Morris L. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010 Jul 17; 24(11):1679-87. PMID: 20453629; PMCID: PMC2894994.
      Citations: 69     Fields:    Translation:HumansCells
    189. Alexandre KB, Gray ES, Lambson BE, Moore PL, Choge IA, Mlisana K, Karim SS, McMahon J, O'Keefe B, Chikwamba R, Morris L. Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. Virology. 2010 Jun 20; 402(1):187-96. PMID: 20392471; PMCID: PMC3401642.
      Citations: 57     Fields:    Translation:HumansCells
    190. Hoffmann CJ, Charalambous S, Sim J, Ledwaba J, Schwikkard G, Chaisson RE, Fielding KL, Churchyard GJ, Morris L, Grant AD. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis. 2009 Dec 15; 49(12):1928-35. PMID: 19911963; PMCID: PMC2789416.
      Citations: 78     Fields:    Translation:HumansCells
    191. Boltz VF, Maldarelli F, Martinson N, Morris L, McIntyre JA, Gray G, Hopley MJ, Kimura T, Mayers DL, Robinson P, Mellors JW, Coffin JM, Palmer SE. Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design. J Virol Methods. 2010 Mar; 164(1-2):122-6. PMID: 19948190; PMCID: PMC4734888.
      Citations: 13     Fields:    Translation:HumansCells
    192. Moore PL, Ranchobe N, Lambson BE, Gray ES, Cave E, Abrahams MR, Bandawe G, Mlisana K, Abdool Karim SS, Williamson C, Morris L, CAPRISA 002 Study, NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI). Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 2009 Sep; 5(9):e1000598. PMID: 19763271; PMCID: PMC2742164.
      Citations: 153     Fields:    Translation:HumansCells
    193. Moore PL, Gray ES, Morris L. Specificity of the autologous neutralizing antibody response. Curr Opin HIV AIDS. 2009 Sep; 4(5):358-63. PMID: 20048698; PMCID: PMC3004050.
      Citations: 46     Fields:    Translation:HumansAnimalsCells
    194. Gray ES, Madiga MC, Moore PL, Mlisana K, Abdool Karim SS, Binley JM, Shaw GM, Mascola JR, Morris L. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol. 2009 Nov; 83(21):11265-74. PMID: 19692477; PMCID: PMC2772769.
      Citations: 70     Fields:    Translation:HumansCells
    195. Singh A, Page T, Moore PL, Allgaier RL, Hiramen K, Coovadia HM, Walker BD, Morris L, Ndung'u T. Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C isolates. Virology. 2009 Oct 10; 393(1):56-67. PMID: 19695656; PMCID: PMC3492694.
      Citations: 8     Fields:    Translation:HumansCells
    196. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med. 2009 Aug; 15(8):866-70. PMID: 19525964.
      Citations: 258     Fields:    Translation:HumansAnimalsCells
    197. Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, Puren A, DeCamp A, Gilbert PB, Wood B, Montefiori DC, Binley JM, Shaw GM, Haynes BF, Mascola JR, Morris L. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol. 2009 Sep; 83(17):8925-37. PMID: 19553335; PMCID: PMC2738176.
      Citations: 127     Fields:    Translation:HumansCells
    198. Martinson NA, Morris L, Johnson J, Gray GE, Pillay V, Ledwaba J, Dhlamini P, Cohen S, Puren A, Steyn J, Heneine W, McIntyre JA. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance. AIDS. 2009 Apr 27; 23(7):809-16. PMID: 19287298.
      Citations: 8     Fields:    Translation:HumansCells
    199. Lopes de Campos WR, Coopusamy D, Morris L, Mayosi BM, Khati M. Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals. Antimicrob Agents Chemother. 2009 Jul; 53(7):3056-64. PMID: 19364860; PMCID: PMC2704642.
      Citations: 6     Fields:    Translation:HumansCells
    200. Davis KL, Gray ES, Moore PL, Decker JM, Salomon A, Montefiori DC, Graham BS, Keefer MC, Pinter A, Morris L, Hahn BH, Shaw GM. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology. 2009 May 10; 387(2):414-26. PMID: 19298995; PMCID: PMC2792036.
      Citations: 63     Fields:    Translation:HumansCellsPHPublic Health
    201. Fenyö EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, Donners H, Heyndrickx L, Alcami J, Bongertz V, Jassoy C, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Sattentau Q, Schuitemaker H, Sutthent R, Wrin T, Scarlatti G. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One. 2009; 4(2):e4505. PMID: 19229336; PMCID: PMC2640999.
      Citations: 78     Fields:    Translation:Humans
    202. Coovadia A, Hunt G, Abrams EJ, Sherman G, Meyers T, Barry G, Malan E, Marais B, Stehlau R, Ledwaba J, Hammer SM, Morris L, Kuhn L. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis. 2009 Feb 15; 48(4):462-72. PMID: 19133804; PMCID: PMC2810158.
      Citations: 53     Fields:    Translation:HumansCells
    203. Kulkarni SS, Lapedes A, Tang H, Gnanakaran S, Daniels MG, Zhang M, Bhattacharya T, Li M, Polonis VR, McCutchan FE, Morris L, Ellenberger D, Butera ST, Bollinger RC, Korber BT, Paranjape RS, Montefiori DC. Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology. 2009 Mar 15; 385(2):505-20. PMID: 19167740; PMCID: PMC2677301.
      Citations: 58     Fields:    Translation:HumansCells
    204. Basson AE, Ntsala M, Martinson N, Tlale E, Corrigan GE, Shao X, Gray G, McIntyre J, Puren A, Morris L. Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr. 2008 Dec 15; 49(5):538-43. PMID: 18989222.
      Citations: 6     Fields:    Translation:HumansCellsPHPublic Health
    205. Davis KL, Bibollet-Ruche F, Li H, Decker JM, Kutsch O, Morris L, Salomon A, Pinter A, Hoxie JA, Hahn BH, Kwong PD, Shaw GM. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol. 2009 Feb; 83(3):1240-59. PMID: 19019969; PMCID: PMC2620909.
      Citations: 44     Fields:    Translation:HumansCells
    206. Pillay V, Pillay C, Kantor R, Venter F, Levin L, Morris L. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2008 Nov; 24(11):1449-54. PMID: 19000027; PMCID: PMC8884175.
      Citations: 24     Fields:    Translation:HumansCells
    207. Gray CM, Mlotshwa M, Riou C, Mathebula T, de Assis Rosa D, Mashishi T, Seoighe C, Ngandu N, van Loggerenberg F, Morris L, Mlisana K, Williamson C, Karim SA, CAPRISA 002 Acute Infection Study Team. Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point. J Virol. 2009 Jan; 83(1):470-8. PMID: 18945774; PMCID: PMC2612312.
      Citations: 33     Fields:    Translation:HumansCells
    208. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT, Cohen M, Eron J, Hicks CB, Liao HX, Self SG, Landucci G, Forthal DN, Weinhold KJ, Keele BF, Hahn BH, Greenberg ML, Morris L, Karim SS, Blattner WA, Montefiori DC, Shaw GM, Perelson AS, Haynes BF. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol. 2008 Dec; 82(24):12449-63. PMID: 18842730; PMCID: PMC2593361.
      Citations: 386     Fields:    Translation:HumansCells
    209. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, Decker JM, Wycuff D, Harris L, Hawkins N, Wood B, Nathe C, Richman D, Tomaras GD, Bibollet-Ruche F, Robinson JE, Morris L, Shaw GM, Montefiori DC, Mascola JR. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol. 2008 Dec; 82(23):11651-68. PMID: 18815292; PMCID: PMC2583680.
      Citations: 240     Fields:    Translation:HumansAnimalsCells
    210. Mosebi S, Morris L, Dirr HW, Sayed Y. Active-site mutations in the South african human immunodeficiency virus type 1 subtype C protease have a significant impact on clinical inhibitor binding: kinetic and thermodynamic study. J Virol. 2008 Nov; 82(22):11476-9. PMID: 18768960; PMCID: PMC2573279.
      Citations: 9     Fields:    Translation:HumansCells
    211. Prendergast A, Mphatswe W, Tudor-Williams G, Rakgotho M, Pillay V, Thobakgale C, McCarthy N, Morris L, Walker BD, Goulder P. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS. 2008 Jul 11; 22(11):1333-43. PMID: 18580613.
      Citations: 47     Fields:    Translation:HumansCellsPHPublic Health
    212. van Loggerenberg F, Mlisana K, Williamson C, Auld SC, Morris L, Gray CM, Abdool Karim Q, Grobler A, Barnabas N, Iriogbe I, Abdool Karim SS, CAPRISA 002 Acute Infection Study Team. Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One. 2008 Apr 16; 3(4):e1954. PMID: 18414658; PMCID: PMC2278382.
      Citations: 140     Fields:    Translation:Humans
    213. Bertagnolio S, Derdelinckx I, Parker M, Fitzgibbon J, Fleury H, Peeters M, Schuurman R, Pillay D, Morris L, Tanuri A, Gershy-Damet GM, Nkengasong J, Gilks CF, Sutherland D, Sandstrom P. World Health Organization/HIVResNet Drug Resistance Laboratory Strategy. Antivir Ther. 2008; 13 Suppl 2:49-57. PMID: 18575191.
      Citations: 19     Fields:    Translation:HumansCellsPHPublic Health
    214. Pillay V, Ledwaba J, Hunt G, Rakgotho M, Singh B, Makubalo L, Bennett DE, Puren A, Morris L. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther. 2008; 13 Suppl 2:101-7. PMID: 18575198.
      Citations: 41     Fields:    Translation:HumansCellsPHPublic Health
    215. Gray ES, Moore PL, Bibollet-Ruche F, Li H, Decker JM, Meyers T, Shaw GM, Morris L. 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response. J Virol. 2008 Mar; 82(5):2367-75. PMID: 18094155; PMCID: PMC2258954.
      Citations: 25     Fields:    Translation:HumansCells
    216. Moore PL, Gray ES, Choge IA, Ranchobe N, Mlisana K, Abdool Karim SS, Williamson C, Morris L, CAPRISA 002 Study Team. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol. 2008 Feb; 82(4):1860-9. PMID: 18057243; PMCID: PMC2258729.
      Citations: 104     Fields:    Translation:HumansCells
    217. Gray ES, Moore PL, Pantophlet RA, Morris L. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. J Virol. 2007 Oct; 81(19):10769-76. PMID: 17634239; PMCID: PMC2045459.
      Citations: 34     Fields:    Translation:HumansCells
    218. Rademeyer C, Moore PL, Taylor N, Martin DP, Choge IA, Gray ES, Sheppard HW, Gray C, Morris L, Williamson C, HIVNET 028 study team. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology. 2007 Nov 10; 368(1):172-81. PMID: 17632196.
      Citations: 31     Fields:    Translation:HumansCells
    219. Martinson NA, Ekouevi DK, Dabis F, Morris L, Lupodwana P, Tonwe-Gold B, Dhlamini P, Becquet R, Steyn JG, Leroy V, Viho I, Gray GE, McIntyre JA. Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr. 2007 Jun 01; 45(2):206-9. PMID: 17438480.
      Citations: 10     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    220. Montefiori DC, Morris L, Ferrari G, Mascola JR. Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination. Curr Opin HIV AIDS. 2007 May; 2(3):169-76. PMID: 19372883; PMCID: PMC3171201.
      Citations: 13     Fields:    
    221. Martinson NA, Morris L, Gray G, Moodley D, Pillay V, Cohen S, Dhlamini P, Puren A, Bhayroo S, Steyn J, McIntyre JA. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr. 2007 Feb 01; 44(2):148-53. PMID: 17117145.
      Citations: 37     Fields:    Translation:HumansCellsPHPublic Health
    222. Seoighe C, Ketwaroo F, Pillay V, Scheffler K, Wood N, Duffet R, Zvelebil M, Martinson N, McIntyre J, Morris L, Hide W. A model of directional selection applied to the evolution of drug resistance in HIV-1. Mol Biol Evol. 2007 Apr; 24(4):1025-31. PMID: 17272680.
      Citations: 24     Fields:    Translation:HumansCells
    223. Walker PR, Ketunuti M, Choge IA, Meyers T, Gray G, Holmes EC, Morris L. Polymorphisms in Nef associated with different clinical outcomes in HIV type 1 subtype C-infected children. AIDS Res Hum Retroviruses. 2007 Feb; 23(2):204-15. PMID: 17331028.
      Citations: 13     Fields:    Translation:HumansCells
    224. Coetzer M, Cilliers T, Papathanasopoulos M, Ramjee G, Karim SA, Williamson C, Morris L. Longitudinal analysis of HIV type 1 subtype C envelope sequences from South Africa. AIDS Res Hum Retroviruses. 2007 Feb; 23(2):316-21. PMID: 17331039.
      Citations: 14     Fields:    Translation:HumansCells
    225. Bessong PO, Mphahlele J, Choge IA, Obi LC, Morris L, Hammarskjold ML, Rekosh DM. Resistance mutational analysis of HIV type 1 subtype C among rural South African drug-naive patients prior to large-scale availability of antiretrovirals. AIDS Res Hum Retroviruses. 2006 Dec; 22(12):1306-12. PMID: 17209775.
      Citations: 16     Fields:    Translation:HumansCells
    226. Walker PR, Cilliers T, Choge IA, Taylor N, Cohen SS, Morris L. High specificity of V3 serotyping among human immunodeficiency virus type-1 subtype C infected patients with varying disease status and viral phenotype. J Med Virol. 2006 Oct; 78(10):1262-8. PMID: 16927278.
      Citations: 1     Fields:    Translation:HumansCells
    227. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, Mlisana K, Karim SA, Hong K, Greene KM, Bilska M, Zhou J, Allen S, Chomba E, Mulenga J, Vwalika C, Gao F, Zhang M, Korber BT, Hunter E, Hahn BH, Montefiori DC. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol. 2006 Dec; 80(23):11776-90. PMID: 16971434; PMCID: PMC1642599.
      Citations: 258     Fields:    Translation:HumansCells
    228. Coetzer M, Cilliers T, Ping LH, Swanstrom R, Morris L. Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology. 2006 Dec 5-20; 356(1-2):95-105. PMID: 16942785.
      Citations: 30     Fields:    Translation:HumansCells
    229. Gray ES, Meyers T, Gray G, Montefiori DC, Morris L. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med. 2006 Jul; 3(7):e255. PMID: 16834457; PMCID: PMC1502151.
      Citations: 47     Fields:    Translation:HumansCellsPHPublic Health
    230. Jensen MA, Coetzer M, van 't Wout AB, Morris L, Mullins JI. A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol. 2006 May; 80(10):4698-704. PMID: 16641263; PMCID: PMC1472078.
      Citations: 67     Fields:    Translation:HumansCells
    231. Cave E, Weinberg MS, Cilliers T, Carmona S, Morris L, Arbuthnot P. Silencing of HIV-1 subtype C primary isolates by expressed small hairpin RNAs targeted to gag. AIDS Res Hum Retroviruses. 2006 May; 22(5):401-10. PMID: 16706616.
      Citations: 6     Fields:    Translation:HumansCells
    232. Choge I, Cilliers T, Walker P, Taylor N, Phoswa M, Meyers T, Viljoen J, Violari A, Gray G, Moore PL, Papathanosopoulos M, Morris L. Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. AIDS Res Hum Retroviruses. 2006 May; 22(5):458-65. PMID: 16706624.
      Citations: 23     Fields:    Translation:HumansCells
    233. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS. 2006 Apr 24; 20(7):995-1002. PMID: 16603851; PMCID: PMC2841686.
      Citations: 44     Fields:    Translation:HumansCellsPHPublic Health
    234. Rhee SY, Kantor R, Katzenstein DA, Camacho R, Morris L, Sirivichayakul S, Jorgensen L, Brigido LF, Schapiro JM, Shafer RW, International Non Subtype B HIV-1 Working Group. HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. AIDS. 2006 Mar 21; 20(5):643-51. PMID: 16514293; PMCID: PMC2551321.
      Citations: 46     Fields:    Translation:HumansCells
    235. Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, Grise H, Corcoran P, Zwick MB, Franti M, Morris L, Roux KH, Burton DR, Binley JM. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol. 2006 Mar; 80(5):2515-28. PMID: 16474158; PMCID: PMC1395414.
      Citations: 215     Fields:    Translation:HumansAnimalsCells
    236. Snoeck J, Kantor R, Shafer RW, Van Laethem K, Deforche K, Carvalho AP, Wynhoven B, Soares MA, Cane P, Clarke J, Pillay C, Sirivichayakul S, Ariyoshi K, Holguin A, Rudich H, Rodrigues R, Bouzas MB, Brun-Vézinet F, Reid C, Cahn P, Brigido LF, Grossman Z, Soriano V, Sugiura W, Phanuphak P, Morris L, Weber J, Pillay D, Tanuri A, Harrigan RP, Camacho R, Schapiro JM, Katzenstein D, Vandamme AM. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother. 2006 Feb; 50(2):694-701. PMID: 16436728; PMCID: PMC1366873.
      Citations: 25     Fields:    Translation:Cells
    237. Loskutoff NM, Huyser C, Singh R, Walker DL, Thornhill AR, Morris L, Webber L. Use of a novel washing method combining multiple density gradients and trypsin for removing human immunodeficiency virus-1 and hepatitis C virus from semen. Fertil Steril. 2005 Oct; 84(4):1001-10. PMID: 16213856.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    238. Cilliers T, Moore P, Coetzer M, Morris L. In vitro generation of HIV type 1 subtype C isolates resistant to enfuvirtide. AIDS Res Hum Retroviruses. 2005 Sep; 21(9):776-83. PMID: 16218801.
      Citations: 5     Fields:    Translation:HumansCells
    239. Cilliers T, Willey S, Sullivan WM, Patience T, Pugach P, Coetzer M, Papathanasopoulos M, Moore JP, Trkola A, Clapham P, Morris L. Use of alternate coreceptors on primary cells by two HIV-1 isolates. Virology. 2005 Aug 15; 339(1):136-44. PMID: 15992849.
      Citations: 18     Fields:    Translation:HumansCells
    240. Mascola JR, D'Souza P, Gilbert P, Hahn BH, Haigwood NL, Morris L, Petropoulos CJ, Polonis VR, Sarzotti M, Montefiori DC. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol. 2005 Aug; 79(16):10103-7. PMID: 16051803; PMCID: PMC1182642.
      Citations: 157     Fields:    Translation:HumansCells
    241. Johnson JA, Li JF, Morris L, Martinson N, Gray G, McIntyre J, Heneine W. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis. 2005 Jul 01; 192(1):16-23. PMID: 15942889.
      Citations: 83     Fields:    Translation:HumansCellsPHPublic Health
    242. Wallis CL, Mahomed I, Morris L, Chidarikire T, Stevens G, Rekhviashvili N, Stevens W. Evaluation of an oligonucleotide ligation assay for detection of mutations in HIV-1 subtype C individuals who have high level resistance to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors. J Virol Methods. 2005 May; 125(2):99-109. PMID: 15794978.
      Citations: 5     Fields:    Translation:HumansCells
    243. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, Clarke J, Sirivichayakul S, Soares MA, Snoeck J, Pillay C, Rudich H, Rodrigues R, Holguin A, Ariyoshi K, Bouzas MB, Cahn P, Sugiura W, Soriano V, Brigido LF, Grossman Z, Morris L, Vandamme AM, Tanuri A, Phanuphak P, Weber JN, Pillay D, Harrigan PR, Camacho R, Schapiro JM, Shafer RW. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005 Apr; 2(4):e112. PMID: 15839752; PMCID: PMC1087220.
      Citations: 100     Fields:    Translation:HumansCells
    244. Gray CM, Williamson C, Bredell H, Puren A, Xia X, Filter R, Zijenah L, Cao H, Morris L, Vardas E, Colvin M, Gray G, McIntyre J, Musonda R, Allen S, Katzenstein D, Mbizo M, Kumwenda N, Taha T, Karim SA, Flores J, Sheppard HW. Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa. AIDS Res Hum Retroviruses. 2005 Apr; 21(4):285-91. PMID: 15943570.
      Citations: 10     Fields:    Translation:HumansCells
    245. Bessong PO, Larry Obi C, Cilliers T, Choge I, Phoswa M, Pillay C, Papathanasopoulos M, Morris L. Characterization of human immunodeficiency virus type 1 from a previously unexplored region of South Africa with a high HIV prevalence. AIDS Res Hum Retroviruses. 2005 Jan; 21(1):103-9. PMID: 15665650.
      Citations: 7     Fields:    Translation:HumansCells
    246. Moore PL, Cilliers T, Morris L. Predicted genotypic resistance to the novel entry inhibitor, BMS-378806, among HIV-1 isolates of subtypes A to G. AIDS. 2004 Nov 19; 18(17):2327-30. PMID: 15577547.
      Citations: 5     Fields:    Translation:Cells
    247. Day JH, Grant AD, Fielding KL, Morris L, Moloi V, Charalambous S, Puren AJ, Chaisson RE, De Cock KM, Hayes RJ, Churchyard GJ. Does tuberculosis increase HIV load? J Infect Dis. 2004 Nov 01; 190(9):1677-84. PMID: 15478075.
      Citations: 27     Fields:    Translation:HumansCells
    248. Grobler J, Gray CM, Rademeyer C, Seoighe C, Ramjee G, Karim SA, Morris L, Williamson C. Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis. 2004 Oct 01; 190(7):1355-9. PMID: 15346349.
      Citations: 52     Fields:    Translation:HumansCells
    249. Cilliers T, Patience T, Pillay C, Papathanasopoulos M, Morris L. Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20. AIDS Res Hum Retroviruses. 2004 May; 20(5):477-82. PMID: 15186521.
      Citations: 9     Fields:    Translation:Cells
    250. Alagiozoglou L, Morris L, Bredell H, Martin DJ, Sitas F. Human herpesvirus-8 antibodies and DNA in HIV-1 infected patients in South Africa. Epidemiol Infect. 2003 Dec; 131(3):1125-9. PMID: 14959780; PMCID: PMC2870062.
      Citations: 4     Fields:    Translation:HumansCells
    251. Morris L, Pillay C, Chezzi C, Lupondwana P, Ntsala M, Levin L, Venter F, Martinson N, Gray G, McIntyre J. Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine. AIDS. 2003 Jul 25; 17(11):1698-700. PMID: 12853755.
      Citations: 13     Fields:    Translation:HumansCellsPHPublic Health
    252. Morris L, Martin DJ, Bredell H, Nyoka SN, Sacks L, Pendle S, Page-Shipp L, Karp CL, Sterling TR, Quinn TC, Chaisson RE. Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J Infect Dis. 2003 Jun 15; 187(12):1967-71. PMID: 12792875.
      Citations: 25     Fields:    Translation:HumansCellsCTClinical Trials
    253. Cilliers T, Nhlapo J, Coetzer M, Orlovic D, Ketas T, Olson WC, Moore JP, Trkola A, Morris L. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol. 2003 Apr; 77(7):4449-56. PMID: 12634405; PMCID: PMC150635.
      Citations: 68     Fields:    Translation:HumansCells
    254. Williamson C, Morris L, Maughan MF, Ping LH, Dryga SA, Thomas R, Reap EA, Cilliers T, van Harmelen J, Pascual A, Ramjee G, Gray G, Johnston R, Karim SA, Swanstrom R. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses. 2003 Feb; 19(2):133-44. PMID: 12639249.
      Citations: 56     Fields:    Translation:HumansAnimalsCells
    255. Cilliers T, Morris L. Coreceptor usage and biological phenotypes of HIV-1 isolates. Clin Chem Lab Med. 2002 Sep; 40(9):911-7. PMID: 12435108.
      Citations: 2     Fields:    Translation:HumansCells
    256. Papathanasopoulos MA, Cilliers T, Morris L, Mokili JL, Dowling W, Birx DL, McCutchan FE. Full-length genome analysis of HIV-1 subtype C utilizing CXCR4 and intersubtype recombinants isolated in South Africa. AIDS Res Hum Retroviruses. 2002 Aug 10; 18(12):879-86. PMID: 12201911.
      Citations: 18     Fields:    Translation:HumansCells
    257. Bredell H, Hunt G, Casteling A, Cilliers T, Rademeyer C, Coetzer M, Miller S, Johnson D, Tiemessen CT, Martin DJ, Williamson C, Morris L. HIV-1 Subtype A, D, G, AG and unclassified sequences identified in South Africa. AIDS Res Hum Retroviruses. 2002 Jun 10; 18(9):681-3. PMID: 12079566.
      Citations: 10     Fields:    Translation:HumansCells
    258. Pillay C, Bredell H, McIntyre J, Gray G, Morris L. HIV-1 subtype C reverse transcriptase sequences from drug-naive pregnant women in South Africa. AIDS Res Hum Retroviruses. 2002 May 20; 18(8):605-10. PMID: 12036490.
      Citations: 8     Fields:    Translation:HumansCells
    259. Morris L. Neutralizing antibody responses to HIV-1 infection. IUBMB Life. 2002 Apr-May; 53(4-5):197-9. PMID: 12120994.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    260. Bures R, Morris L, Williamson C, Ramjee G, Deers M, Fiscus SA, Abdool-Karim S, Montefiori DC. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol. 2002 Mar; 76(5):2233-44. PMID: 11836401; PMCID: PMC135941.
      Citations: 52     Fields:    Translation:HumansCells
    261. Alagiozoglou L, Sitas F, Morris L. Phylogenetic analysis of human herpesvirus-8 in South Africa and identification of a novel subgroup. J Gen Virol. 2000 Aug; 81(Pt 8):2029-2038. PMID: 10900042.
      Citations: 4     Fields:    Translation:HumansCells
    262. Silber E, Sonnenberg P, Ho KC, Koornhof HJ, Eintracht S, Morris L, Saffer D. Meningitis in a community with a high prevalence of tuberculosis and HIV infection. J Neurol Sci. 1999 Jan 01; 162(1):20-6. PMID: 10064164.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    263. Silber E, Sonnenberg P, Koornhof HJ, Morris L, Saffer D. Dual infective pathology in patients with cryptococcal meningitis. Neurology. 1998 Oct; 51(4):1213-5. PMID: 9781566.
      Citations: 8     Fields:    Translation:HumansCells
    264. Morris L, Silber E, Sonnenberg P, Eintracht S, Nyoka S, Lyons SF, Saffer D, Koornhof H, Martin DJ. High human immunodeficiency virus type 1 RNA load in the cerebrospinal fluid from patients with lymphocytic meningitis. J Infect Dis. 1998 Feb; 177(2):473-6. PMID: 9466541.
      Citations: 18     Fields:    Translation:HumansCells
    Morris's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (573)
    Explore
    _
    Co-Authors (30)
    Explore
    _
    Similar People (60)
    Explore
    _